

**REMARKS**

Claims 1-11, 20-23, 47 and 48, as amended, and new claims 49-59 appear in this application for the Examiner's active review. Claims 1 and 20 have been amended to further define the invention by reciting "peptide derived from D2 of the extracellular domain of the NKp46 receptor," support for which is found in the specification, e.g., paragraphs [0001], [0012], [0013], [0018] and [0020] of the published application. Claims 3 and 4 have been amended to be consistent with changes made to claim 1. Accordingly, claims 12-19, 36 and 37 have been cancelled. Claims 34 and 38 have been amended to depend from claim 1. Claim 47 has been amended to recite preferred embodiments. Claim 48 has been amended to recite "at an amino acid residue selected from the group consisting of Threonine 125, Threonine 225 and Asparagine 216 within the D2 domain," support for which is found in the specification, for example at paragraph [0069] of the published application. New claim 49 reciting "the single amino acid substitution is selected from the group consisting of: Threonine 225 replaced by an amino acid residue selected from the group consisting of Serine, Alanine and Asparagine; Threonine 125 replaced by Alanine, and Asparagine 216 replaced by Alanine" is supported by the specification, for example paragraphs [0069] and [0028] of the published application. New claim 50 reciting "one or more glycosylation sites within the proximal domain of the NKp46 receptor" is supported by the specification, for example paragraph [0069] of the published application. New claim 51 is supported by the specification, for example paragraphs [0016], [0070], [0164]-[0168], [0177], [0178] of the published application and claim 2 as filed. Support for new claim 52 is found in the specification, for example at paragraphs [0016], [0164] and [0167] of the published application and claim 9 as filed while support for new claims 53-55 is found in the specification, for example at paragraphs [0069], [0070], [0177], [0178] and [0183] of the published application and claim 1 as filed. Support for new claims 56 and 57 is found in the specification, for example at paragraph [0070] of the published application. Support for new claims 58 and 59 is found in the specification, for example at paragraphs [0143] and [0177] of the published application, and claims 22-23 as filed. Claims 24-27 have also been cancelled herewith. Applicants respectfully reserve the right to file a divisional or continuation application for any claims cancelled during the prosecution of this application. As no new matter has been introduced by any of these changes and additions, the claim amendments should all be entered at this time.

Claims 1-11, 20-27 and 47-48 have been rejected under 35 U.S.C.112, first paragraph for allegedly failing to satisfy the enablement requirement. The Examiner acknowledges that the specification is “enabling for an isolated NKp46D2 peptide fragment or a fusion protein comprising the natural cytotoxicity receptor NKp46 and the Fc portion of human IgG1, (NKp46-Ig), said molecules which bind to a viral infected cell or to a tumor cell.” As claims 1 and 20 as amended now specify that the claimed peptide fragment of NKp46 and fusion protein comprising same, comprise a peptide derived from D2 of the extracellular domain of NKp46, these claims as amended, and claims dependent thereon, are fully enabled by the specification, and relate to subject matter that was in the possession of the inventors at the time the application was filed.

More specifically, Applicants respectfully refer to the enclosed Rule 132 Declaration of co-inventor Angel Porgador (referred to hereinafter “the Declaration”). The Declaration describes the synthetically produced peptides designated Peptide #7, Peptide #12 and Peptide #13, each of which is 20 amino acids in length. Peptide #7, Peptide #12 and Peptide #13 correspond respectively to amino acid residues 151-170, 176-195 and 181-200 of NKp46 isoform a. Thus, each of these peptides corresponds to a peptide fragment of the D2 domain of NKp46, which spans amino acid residues 121-254 of NKp46 isoform a (see, e.g., paragraph [0007] of the published application). Moreover, the Declaration discloses that each of Peptide #7, Peptide #12 and Peptide #13 directly binds to HeLa human cancer cells. Accordingly, the Declaration provides enabling support for an isolated peptide fragment of NKp46, comprising a peptide derived from D2 of the extracellular domain of NKp46, wherein the isolated peptide fragment is about 10-100 amino acid residues in length and wherein said peptide fragment exhibits at least one activity selected from binding to a viral infected cell or binding to a tumor cell, as recited and claimed in claims 1 and 20 as amended.

Claim 47 as amended is drawn to a variant polypeptide of the natural cytotoxicity receptor NKp46, the variant comprising at least a single amino acid substitution in an epitope required for the recognition of viral-infected cells or tumor cells, wherein the epitope is in the proximal domain of the NKp46 receptor. Claim 47 as amended does not recite the allegedly non-enabled term “an active fragment thereof”. Applicants respectfully submit that the subject matter of claim 47 is enabled by the specification and additional disclosures by the inventors, in particular, the enclosed PCT Application Publication No. WO 2005/051973 (hereinafter “WO ‘973”) of the present inventors, which was filed and published after the filing date of the present

application. The corresponding US national phase application of WO '973 was filed as US Patent Application No. 10/580,428, which is now abandoned, as noted in the Office Action. WO '973 discloses production and analysis of the NKp46 D2 substitution mutants Q4 and Q4T1, each of which has the mutations K157Q, R160Q, H163Q, and R166Q within a fragment of the D2 domain of NKp46. In addition, Q4T1 has the mutation K170T. These mutations were made at positively charged residues in the putative heparin binding domain of NKp46D2 (see, e.g., Example 5, pages 33-34; page 11, lines 12-13 of WO '973). WO '973 further discloses that the corresponding Ig fusion proteins of these mutants, NKp46D2-Q4-Ig and NKp46D2-Q4T1-Ig respectively, bind to influenza virus infected cells, in a manner similar to that of NKp46D2-Ig (see, e.g., page 34, lines 23-25 of WO '973,). Thus, at the time the application was filed, Applicants were in possession of a variant NKp46 polypeptide commensurate in scope with claim 47 as amended. Moreover, the subject matter of claim 48 as amended corresponds to subject matter deemed in the Office Action as enabled by the specification, namely a variant NKp46 polypeptide comprising an amino acid substitution at an amino acid residue selected from Threonine 225, Threonine 125 and Asparagine 216.

Dependent claims 49-59 recite and claim embodiments of substitution mutants; glycosylation characteristics of the claimed variant; binding activities exhibited by the claimed variant, and fusion proteins comprising the claimed variant, which are also enabled by the specification. More specifically, the specification teaches that the proximal domain (D2) of NKp46 includes three putative glycosylation sites, i.e., O-linked glycosylation sites at Threonine 125 and at Threonine 225, and an N-linked glycosylation site at Asn 216 (see, e.g., paragraph [0069] of the published application). The specification also teaches production and analysis of NKp46D2 substitution mutants at each of these sites, i.e., substitution at Thr225 with either Serine, Alanine or Asparagine; substitution at Thr 125 with Alanine, and substitution at Asn 216 with Alanine (see, e.g., paragraphs [0028] and [0069] of the published application). The specification further teaches that various of these substitution mutants retain the ability to bind to viral-infected cells and tumor cells, although Thr 225 appears to be essential for both types of binding, with the binding to viral-infected cells being glycosylation-dependent, and the binding to tumor cells being glycosylation-independent (see, e.g., paragraphs [0028], [0069] and [0177]-[0184] of the published application). The specification further teaches the production of the subject substitution mutants as fusion proteins with the Fc fragment of Ig (see, e.g., paragraphs

[0149] and [0177] of the published application). The experimental results described in Examples 5 and 6, and depicted in Figures 6-8 also indicate that the inventors were in full possession of the claimed invention at the time the application was filed. Therefore, the rejection under 35 U.S.C.112, first paragraph, should be withdrawn.

Accordingly, the entire application is now in condition for allowance, early notice of which would be appreciated. Should the Examiner not agree with the Applicants' position, then a personal or telephonic interview is respectfully requested to discuss any remaining issues and expedite the eventual allowance of the application.

Date

3/31/10

Respectfully submitted,



Allan A. Fanucci, Reg. No. 30,256

**WINSTON & STRAWN LLP**

**Customer No. 28765**

(212)-294-3311

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
9 June 2005 (09.06.2005)

PCT

(10) International Publication Number  
**WO 2005/051973 A2**

- (51) International Patent Classification<sup>7</sup>: C07K (74) Agent: WEBB, Cynthia; Webb & Associates, P.O. Box 2189, 76121 Rehovot (IL).
- (21) International Application Number: PCT/IL2004/001081 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 24 November 2004 (24.11.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/524,648 25 November 2003 (25.11.2003) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicants (for all designated States except US): YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; High Tech Park, Edmond J. Safra Campus, P.O. Box 39135, 91390 Givat Ram, Jerusalem (IL). BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY [IL/IL]; P.O. Box 653, 84105 Beer-Sheva (IL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MANDELBOIM, Ofer [IL/IL]; 58 Hayarden Street, 73142 Shoham (IL). PORGADOR, Angel [IL/IL]; 11 Tavlan Street, 85338 Lehavim (IL).
- Published:  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2005/051973 A2

(54) Title: PEPTIDES DERIVED FROM NATURAL CYTOTOXICITY RECEPTORS AND METHODS OF USE THEREOF

(57) Abstract: The present invention relates in general to specific NCR-derived peptides capable of binding to membranc-associated biomolecules of the tumor cells, said biomolecules comprising at least one sulfated polysaccharide. Preferred peptides are about 7 to about 120 amino acids in length and are derived from NKp-44, NKp30 or NKp46.

**PEPTIDES DERIVED FROM NATURAL CYTOTOXICITY RECEPTORS  
AND METHODS OF USE THEREOF**

**FIELD OF THE INVENTION**

5       The present invention relates generally to peptides derived from specific natural cytotoxicity receptors, the peptides capable of binding to membrane-associated biomolecules of tumor and virus infected cells, said biomolecules comprising at least one sulfated polysaccharide, therapeutic compositions comprising the peptides and methods of use thereof.

10

**BACKGROUND OF THE INVENTION**

Natural Killer Cells

      Natural Killer (NK) cells are a class of lymphocytes able to destroy virus-infected and transformed cells apparently without prior antigen stimulation (1, 2). The  
15       interaction between NK cells and their targets is mediated via a complex array of NK inhibitory and activating receptors (3-7). The ligands of the NK cell surface inhibitory receptors are polymorphic and non-polymorphic major histocompatibility complex (MHC) class I molecules (3-7). Some NK cells express activation receptors specific for MHC class I molecules homologous to various NK inhibitory receptors (3-7).

20       Three lysis receptors, expressed mainly on human NK cells, have been identified. They are referred to as natural cytotoxicity receptors (NCR) and include the NKp30, NKp44, and NKp46 molecules (3, 5). The NCR are capable of mediating direct killing of tumor and virus-infected cells and are specific for non-MHC ligands. The NCR are highly NK specific, with NKp46 and NKp30 present exclusively on NK cells, whether  
25       resting or activated, and NKp44 expressed specifically by activated NK cells (3, 5).

      International Patent Publication WO 02/08287 of the present inventors discloses NK receptor fusion proteins in which an extracellular portion of a NK receptor is conjugated to an active segment comprising an immunoglobulin (Ig), a cytotoxic moiety or an imaging moiety. WO 02/08287 further discloses that the NK receptor  
30       fusion proteins exhibit specific interaction with tumor cells and viral-infected cells *in vitro*, and these fusion proteins are disclosed as useful for therapeutic applications *in*

*vivo*. Specific fusion proteins are disclosed and claimed only for NKp46 and NKp44. The teachings of WO 02/08287 are incorporated herein as if set forth herein in their entirety.

5 PCT application publication WO 2004/053054 of the present inventors discloses that NK fusion proteins comprising the natural killer cytotoxicity receptor NKp30 or active fragments thereof were found to be especially effective in inhibiting the growth of tumors *in vivo*. The disclosure further relates to synthetic peptides and fusion proteins comprising NKp30-derived peptide sequences.

10 PCT application PCT/IL2004/000583 of the present inventors discloses peptides and fusion proteins comprising active glycosylated fragments derived from natural killer cytotoxicity receptors NKp44 and NKp46 that are effective in binding to viral-infected cells and tumor cells. An essential epitope involved in the binding of the NKp46 receptor to viral-infected and tumor cells comprises the threonine 225 (T225) residue, one of the O-glycosylated residues of this molecule. It was further disclosed  
15 that a membrane linker peptide derived from the extracellular domain of the human NKp44 receptor is an essential feature in binding to viral infected cells. This linker peptide comprises a hyper-glycosylated region comprising 14 predicted glycosylation sites, which contribute to the efficient binding to viral-infected cells.

PCT publication WO 01/36630 teaches NKp30 specific antibodies that bind to the  
20 NKp30 structure, and to the pharmaceutical and therapeutic uses thereof. That application discloses NKp30 polypeptide sequences, including specific peptides comprising amino acids 139-157 and amino acids 157-190, useful as antigens in the production of anti-NKp30 antibodies.

#### NCR Ligands

25 The identification of the ligands recognized by the NCR is important for further progress in the NK field. The inventors of the present invention have recently shown that the NKp46 and NKp44 proteins, but not NKp30, recognize hemagglutinin (HA) of influenza virus and hemagglutinin-neuraminidase (HN) of Sendai virus (8-10). The recognition of HA and HN requires the sialylation of NKp46 and NKp44  
30 oligosaccharides. The binding of these NCR to hemagglutinins is required for the lysis of virus-infected cells by NK cells (9, 10).

Previous attempts to identify recognition structures exclusive to the interaction between NK cells and tumor cells have been unsuccessful, although important components on both NK cells and on tumor cells that contribute to cellular adhesion and regulation of the cytolytic process have been revealed. These receptor-ligand interactions, however, are not unique to NK cells since they also occur between T lymphocytes and their respective target cells (11). The surface molecules responsible for NK cell-specific receptor-ligand interactions still remain largely unknown.

#### Heparan Sulfate Proteoglycans

Membrane-associated heparan sulfate proteoglycans (HSPGs) are known to play important roles in many aspects of cell behavior, including cell-cell and cell-extracellular matrix adhesion and growth factor signaling. Two families of polypeptides appear to carry the majority of the heparan sulfate on mammalian cells: glypicans, which are attached to the plasma membrane via glycosylphosphatidylinositol (GPI) anchors, and syndecans, which are transmembrane proteins. Commonly, cells express multiple HSPGs, from both the glypican and syndecan families.

The role of HSPGs in growth factor signaling has been best characterized with respect to fibroblast growth factors (FGFs), which require the presence of heparan sulfate for high affinity binding to their tyrosine kinase receptors. The requirement of heparan sulfate for FGF signaling is disclosed, for example in US patent 5,789,182. More recently, several other growth factors have been found to exhibit a strong requirement for an HSPG coreceptor in their signaling (for review see reference 29). These include for example heparin-binding EGF-like growth factor (HB-EGF), hepatocyte growth factor (HGF), and members of the Wnt family of secreted glycoproteins. Many other growth factors, including vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), transforming growth factors (TGFs), and bone morphogenetic proteins (BMPs), are known to bind heparin and heparan sulfate, although the physiological consequences of this binding are unclear.

Previous work in tumor cell recognition revealed that membrane-associated heparan sulfate proteoglycans in transformed cells are either over-expressed or modified in their glycosaminoglycan (GAG) content (12-15). For example, glypican 1 which is attached to the plasma membrane via glycosylphosphatidylinositol (GPI) anchors was reported to be overexpressed in breast and pancreatic cancer (12, 13). In



another example, aberrant methylation of the heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) gene was found in human breast cancer cells, indicating that silencing of an enzyme associated with the sulfation of heparan sulfate is linked to breast tumors (15).

- 5        There exists a long-felt unmet need for identification of the cellular targets of NCR which are responsible for the specific lysis of tumor cells by NK cells. These cellular targets may be used to develop tumor-specific diagnostic, therapeutic and imaging agents.

10        **SUMMARY OF THE INVENTION**

The present invention is based in part on the unexpected discovery that the lysis of tumor cells by NK cells is mediated by the binding of the NK cell, via their natural cytotoxicity receptors (NCRs), to specific sulfated polysaccharide biomolecules of the tumor cells.

- 15        In one aspect, the present invention relates to specific isolated NCR-derived peptides capable of binding to membrane-associated biomolecules of the tumor cells, the biomolecules comprising at least one sulfated polysaccharide. According to one embodiment the at least one sulfated polysaccharide is heparan sulfate. Thus, according to one preferred embodiment the peptides of the present invention are
- 20        capable of binding to heparan sulfate in a tumor cell. These peptides are derived from specific domains of the NCR participating in the interaction with heparan sulfate in the target tumor cell. It is to be clearly understood that the peptides of the invention are smaller than the intact domains of the NCRs from which they are derived.

- In one embodiment, the peptides are derived from the D2 domain of NKp46. In one
- 25        specific embodiment, such peptides comprise the amino acid sequence: FLLLKEGRSSHVQRGYGKVQAEF denoted herein SEQ ID NO:1, which corresponds to amino acid residues 153-175 of NKp46, or an active fragment, analog or derivative thereof. In one specific embodiment the peptide comprises amino acid sequence: FLLLKEGRSSHVQRGYGKVQ corresponding to amino acids 153-172
- 30        (Note: the peptide sequence comprising amino acids 153-172 of NKp46 corresponds to

amino acids 132-151 of the receptor given PDB code "1oll". 1oll is a fragment of the extracellular region of NKp46, residues 25-212, used in crystallization studies).

In another embodiment, the peptides are derived from NKp30. In one specific embodiment, such peptides comprise the amino acid sequence:  
5 RDEVVPGKEVRNGTPEFRGRLAPLASSR denoted herein SEQ ID NO:3, which corresponds to amino acid residues 57-84 of NKp30, or an active fragment, analog or derivative thereof. In another specific embodiment, the peptides comprise the amino acid sequence RDEVVPGKEVRNGTPEFRGR denoted herein as SEQ ID NO:4, which corresponds to amino acid residues 57-76 of NKp30, or an active fragment,  
10 analog or derivative thereof.

In yet another embodiment, the peptides are derived from NKp44. In one specific embodiment, such peptides comprise the amino acid sequence:  
KKGWCKEASALVCIRLVTSKPRRT denoted herein as SEQ ID NO:5, which corresponds to amino acid residues 51-74 of NKp44, or an active fragment, analog or  
15 derivative thereof.

The peptides according to the present invention include both linear and cyclic peptides and modified peptides including peptidomimetics, and amidated peptides. A peptide derivative according to the present invention refers to a peptide having various changes, substitutions, insertions, and deletions so long as the peptides retain binding  
20 activity. It is to be explicitly understood that the NCRs from which the active fragments are derived, may be of human or non-human origin. Though the human sequences are preferred, non-human primates or even lower mammalian species may be a suitable source for derivation of the active fragments according to the invention. It is further to be explicitly understood that the target cells may be human, as well as non-  
25 human mammalian or even avian.

In another aspect, the present invention relates to a method of targeting a tumor cell in a subject in need thereof via an NCR-dependent mechanism, said method comprising administering to the subject an NCR-derived peptide capable of binding to a membrane-associated biomolecule of the tumor cell, the biomolecule comprising at  
30 least one sulfated polysaccharide. Accordingly, the present invention relates to the use of an NCR-derived peptide capable of binding to a membrane-associated biomolecule

of a tumor cell, the biomolecule comprising at least one sulfated polysaccharide, for the preparation of a medicament useful for targeting a tumor cell.

An NCR derived peptide useful for targeting a tumor cell is useful in the diagnosis, imaging and treatment of benign and malignant tumors and proliferative disease.

5 Different membrane-associated biomolecules comprising at least one sulfated polysaccharide may serve as a target for the peptides of the present invention. The biomolecules comprising a sulfated polysaccharide include but are not limited to glycosaminoglycans such as heparin, heparan sulfates or dermatan sulfates.

10 One preferred glycosaminoglycan, which is a binding target for the peptides of the present invention, is heparan sulfate. Other biomolecules comprising a sulfated polysaccharide are glycosaminoglycans covalently attached to proteins such as proteoglycans. Preferred examples of proteoglycans are heparan sulfate proteoglycans (HSPG). HSPG may be divided into two families: glypicans, which are attached to the plasma membrane via glycosylphosphatidylinositol (GPI) anchors, and syndecans,  
15 which are transmembrane proteins.

The NCR-derived peptides according to the present invention include active fragments of the NCR but are not limited to a specific size range. However, according to one embodiment of the present invention, the invention provides peptides comprising between about 7 to about 120 amino acid residues in total, preferably between about 8  
20 to about 100 amino acid residues, more preferably the peptides are less than about 50 amino acid residues, preferably about 10 to about 50 amino acids. The present invention also provides peptides in which the core motif sequence is artificially incorporated within a sequence of a polypeptide, including peptides manufactured by recombinant DNA technology or chemical synthesis.

25 It is to be understood explicitly that the peptides of the present invention are other than full-length NCR polypeptides, linker peptides of the NCR extracellular domains and fragments of an NCR previously disclosed in the art. The present invention excludes specific peptides claimed in WO 02/08287, WO 2004/053054 and PCT application PCT/IL2004/000583.

30 The NCR-derived peptides of the present invention are capable of binding to specific sulfated polysaccharide biomolecules of the tumor cells. The present invention

encompasses NCR-derived peptides incorporated into fusion proteins or conjugated to another molecule or active segment such as immunoglobulin (Ig) or the Fc fragment thereof in order to induce the lysis of tumor cells. Within the scope of the present invention it is contemplated that the binding of the NCR-derived peptides of the present  
5 invention may suffice to activate the lysis process in the target tumor cell.

In another aspect, the present invention encompasses antibodies capable of binding to membrane-associated target biomolecules in a tumor cell. In certain embodiments the antibody is capable of mediating NCR-dependent lysis. Such antibodies specifically recognize one or more epitopes present on such target biomolecules  
10 mediating the lysis of tumor cells by NK cells via the NCR, said target biomolecules comprising at least one sulfated polysaccharide. According to a specific embodiment, the antibodies bind to a specific heparan sulfate epitope on the target tumor cell, thereby activating the NCR-dependent lysis.

In another aspect, the present invention encompasses specific antibodies capable of  
15 blocking the binding of NK cells via their NCR to the membrane-associated target biomolecules in a tumor cell, thereby inhibiting NCR-dependent activity in autoimmunity. A preferred example is an antibody capable of binding to heparan sulfate-associated biomolecules which mediate NCR-dependent lysis.

The present invention also relates to a method for the selective removal of tumor  
20 cells from a biological sample which comprises the selective removal of those cells positive for membrane associated biomolecules, the biomolecule comprising at least one sulfated polysaccharide. The method comprises the steps of contacting the biological sample with an antibody of the present invention under conditions appropriate for immune complex formation, and removing the immune complex formed  
25 from the biological sample.

The present invention can utilize serum immunoglobulins, polyclonal antibodies or fragments thereof, or monoclonal antibodies or fragments thereof having at least a portion of an antigen binding region, including Fv, F(ab)<sub>2</sub>, Fab fragments, single chain antibodies, chimeric or humanized antibodies.

30 The present invention further relates to a method of targeting a tumor cell in a subject in need, said method comprises administering to the subject an NCR-derived peptide capable of binding to a membrane-associated bio-molecule in the tumor cell,

the membrane-associated biomolecule comprising the sulfated polysaccharide according to the present invention.

In the targeting method, preferred NCR-derived peptides according to the present invention are capable of binding to heparan sulfate in a tumor cell. These peptides are derived from specific domains of the NCR participating in the interaction with heparan sulfate in the target tumor cell.

In one embodiment, the peptides derive from the D2 domain of NKp46. In one preferred example, such peptides comprise the amino acid sequence denoted herein SEQ ID NO:1 and SEQ ID NO:2. In another embodiment, the peptides derive from NKp30. In one preferred example, such peptides comprise the amino acid sequence denoted herein SEQ ID NO:3 or SEQ ID NO:4. In yet another embodiment, the peptides derive from NKp44. In one specific embodiment, such peptides comprise the amino acid sequence denoted herein SEQ ID NO:5.

According to yet another aspect, the present invention further relates to pharmaceutical compositions comprising a peptide or a polypeptide of the present invention and a pharmaceutically acceptable carrier. The present invention further encompasses methods of using these compositions for the treatment of malignant and benign tumors including cancer.

The present invention further provides methods of identifying peptides derived from NCR, such peptides capable of targeting tumor cells, by binding to a biomolecule associated with the tumor cells. The present invention further provides methods of identifying peptides derived from NCR, such peptides capable of targeting tumor cells, and mediating lysis upon binding to a biomolecule associated with the tumor cells.

Therefore, according to another aspect the present invention provides a method of identifying peptides derived from NCR which are capable of binding to a biomolecule associated with a tumor cell, the biomolecule comprising at least one sulfated polysaccharide, the method comprising the steps of:

- a) providing a set of candidate peptides;
- b) contacting the peptides with a tumor cell;
- c) determining the binding of said peptides to said tumor cell; and

d) isolating said bound peptides.

These and further embodiments will be apparent from the detailed description and examples that follow.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

5       **Figure 1** demonstrates the effect of 6-O-sulfo-LacNAc-PAA on binding of NKp30-Ig and NKp46D2-Ig to tumor cells. **(A)**: Staining of HeLa cells. Results are presented as median fluorescence intensity (MFI). **(B)** and **(C)**: Staining of HeLa and PC-3 cells, respectively. Results are presented as percentage of binding as compared to staining of cells with NKp46D2-Ig alone without Glyc-PAA mix.

10       **Figure 2** demonstrates the effect of heparin/heparan sulfate on binding of NKp30-Ig and NKp46D2-Ig to tumor cells. **(A)**: Staining of HeLa cells. Results are presented as MFI; the background staining with CD99-Ig, which does not bind to HeLa cells, was 2 to 3. **(B)**, **(C)** and **(D)**: Staining of HeLa, PC-3, and HeLa cells, respectively. Results are presented as percentage of binding as compared to staining of cells with NKp46D2-Ig alone, in absence of the GAG or proteoglycan mix.

15       **Figure 3** demonstrates the effect of heparin/heparan sulfate on binding of NKp44-Ig and NKp44D-Ig to tumor cells. Figures 3B and 3C show binding of NKp44-Ig to different GAGS. Figure 3B shows HeLa cells, Figure 3C shows PC-3 cells. Results are presented as percentage of binding as compared to staining of cells with NKp44-Ig alone without GAG premix.

20       **Figure 4** shows the effect of polysaccharide-degrading enzymes and D-mannosamine on binding of NKp30-Ig and NKp46D2-Ig to tumor cells. HeLa **(A)** and 1106 melanoma **(B)** cells were incubated in reaction buffer alone (mock treatment) or reaction buffer containing a GAG-degrading enzyme. After incubation cells were washed and stained with fusion-Igs. **(C)** Staining with NKp46D2-Ig of EB lymphoma, mock-transfected EB and heparanase-transfected EB that express a functional heparanase on the cell surface (EB-SP) **(D)** Staining with fusion Igs of HeLa cells pretreated with 40mM D-mannosamine overnight. Results are presented as MFI.

25       **Figure 5** shows the effect of heparin-degrading enzymes, heparan sulfate deficiency and glypican-1 suppression on binding of NKp44-Ig to tumor cells. **(A)** PC-3 cells were incubated in reaction buffer alone or containing a GAG-degrading enzyme.

After incubation, cells were washed and stained with fusion Igs. (B1,2) Staining of parental CHO-K1, heparan sulfate-negative and chondroitin sulfate-negative CHO pgsA-745, and heparan sulfate-negative and chondroitin sulfate high-positive CHO pgsD-677 by NKp44-Ig and human (h) second Ab (primary FACS histogram overlay). (B3, B4) Staining of parental CHO-K1 and CHO pgsA-745 with HS4E4 and mouse (m) second Ab. (C1, C2, C3) Staining of Sham and GAS-6 cells with NKp44-Ig, HS4E4 and hIgG1, respectively (primary FACS histogram overlay). Results are from 1 representative experiment of 2. For all panels, MFI results are the average of 2 different samples assayed in the same experiment. Bars,  $\pm$  SD.

Figure 6 shows the effect of 6-O-sulfo-N-acetylglucosamine and target cell-surface heparanase on lysis by primary NK lines. (A) Primary NK line cells were mixed with incremented amounts of Glyc-PAA and added to Eu-labeled target cells for a 4 h lysis assay. Final concentrations of the disaccharides ranged between 0.225 to 0.9 mM. E:T ratio is 50:1. (B) Lysis by primary NK lines of EB, EB-mock transfected and transfected EB-expressing a functional cell-surface heparanase (EB-SP).

Figure 7 shows that the binding of NKp46 and NKp30 to mutant CHO cells lacking HSPG is significantly reduced as compared to wt CHO cells (A). Panel (B) demonstrates that the lysis of mutant CHO cells lacking HSPG by NK cells is significantly lower than lysis of wt CHO cells.

Figure 8 shows the electrostatic potential surface of NKp46 (PDB code:1oll). The potential map was calculated and depicted using the program Delphi and Grasp. The surface is marked such that dark areas labeled with an arrow are those having a negative potential ( $-4\text{kt/e}$ ) unlabeled dark areas are those having a positive potential ( $+4\text{kt/e}$ ). The positive patch can be seen clearly at the D2 domain of the map. The location of the N-terminus (within the D1 domain) and the C-terminus (within the D2 domain).

Figure 9 shows superimposition of FN14 and D2 domain of NKp46. Both proteins are depicted in a solid ribbon presentation, for FN14 and NKp46, respectively. Side chains of basic residues associate with HBS-2 in FN14 and the positively charged region in NKp46 are depicted in ball and stick and colored in gray and black respectively. The residue legends corresponds to the color of the side chains.

Figure 10 shows the binding of NKp46D2-Ig, NKp46D2-Q4-Ig and NKp46D2-Q4T1-Ig to non-infected and IV-infected cells.

### **DETAILED DESCRIPTION OF THE INVENTION**

In order that this invention may be better understood, the following terms and definitions are herein provided.

The term "target cells" are cells that are killed by an NCR-dependent mechanism. The target cells express specific sulfated polysaccharide biomolecules and include, in particular, cells that are malignant or otherwise derived from solid as well as non-solid tumors.

The term "NKp46" refers to a natural cytotoxicity receptor expressed on human NK cells that is capable of mediating direct killing of tumor and virus-infected cells. The term "D2 fragment of NKp46" or "NKpD2" refers to domain 2 (the proximal domain) of the NKp46 molecule corresponding to amino acids 121-249 of NKp46.

Heparan sulfate proteoglycans (HSPG) are macromolecules composed of a core protein covalently O-linked to repeating hexuronic and D-glucosamine disaccharide units.

A "glycosaminoglycan" or "GAG" as used herein refers to a long, unbranched polysaccharide molecule found on the cell surface or extracellular matrix. Non-limiting examples of glycosaminoglycans include heparin, chondroitin sulfate, dextran sulfate, dermatan sulfate, heparan sulfate, keratan sulfate, crosslinked or non-crosslinked hyaluronic acid, hexuronyl hexosaminoglycan sulfate, and inositol hexasulfate.

The present invention is based on the first direct proof that saccharides, preferably polysaccharides such as heparan sulfate are potent inhibitors of the binding of NKp30-Ig and NKp46D2-Ig fusion proteins to tumor cells. The structural characteristics of heparin mediating the high affinity binding of NCR to a tumor cell are specific and restricted to highly O-sulfated oligosaccharides. The 6-O-sulfo-N-acetylglucosamine is a building stone of heparin/heparan sulfate. It is further disclosed herein that target cell membrane-associated heparan sulfate proteoglycans (HSPGs) are recognized by NKp30-Ig and NKp46D2-Ig. The tumor membrane HSPGs are involved in lysis of target tumor cells by NK cells. Finally, it is now disclosed that the NKp46 three dimensional model revealed the existence of a loop in the second domain of NKp46,



between amino acids (aa) 153 to aa 175, with a significant similarity to the heparin binding site 2 (HBS-2) of human fibronectin. Based on a crystal structure of fibronectin type III repeats 12-14 (FN12-14) and biochemical analysis, it is shown that 5 positively-charged amino acids in FN14 (Lys 216, Lys 219, Arg 225, Arg 230 and Lys 261) are critical for fibronectin binding to heparin through HBS-2. The position of the 5 positively-charged aa in the 153-175 loop of NKp46 strikingly overlapped these 5 positively-charged aa of HBS-2.

In one aspect, the present invention relates to specific NCR-derived peptides capable of binding to heparan sulfate in a tumor cell. These peptides are derived from specific domains of the NCR participating in the interaction with heparan sulfate in the target tumor cell.

In one embodiment, the peptides are derived from the D2 domain of NKp46. In one preferred example, such peptides comprise the amino acid sequence denoted as SEQ ID NO:1 or SEQ ID NO:2. In another embodiment, the peptides are derived from NKp30. In one preferred example, such peptides comprise the amino acid sequence denoted as SEQ ID NO:3 or SEQ ID NO:4. In yet another embodiment, the peptides are derived from NKp44. In one preferred example, such peptides comprise the amino acid sequence denoted as SEQ ID NO:5. These peptides are capable of binding to membrane-associated biomolecules in the tumor cells comprising at least one sulfated polysaccharide.

The targeting peptides of the present invention bind to a molecule or structure comprising at least one sulfated polysaccharide that is present preferably only in tumor cells. However, the targeting peptides may bind to a molecule or structure comprising at least one sulfated polysaccharide that is present both in tumor cells and in non-tumor cells. In this case, however, it is preferable that the molecule or structure comprising the sulfated polysaccharides is present in greater amounts in the tumor cells than in the non-tumor cells. Preferably, the molecule or structure comprising the sulfated polysaccharides is present at least at 10-fold higher levels in tumor cells than non-tumor cells. Such molecule or structure may be present at 1000-fold or even higher levels in tumor cells as compared to non-tumor cells.

As disclosed hereinabove, the targeting peptides of the present invention bind to a molecule or structure comprising at least one sulfated polysaccharide. In one

embodiment, the molecule or structure comprising the sulfated polysaccharides covalently attached to a protein core. One examples of such sulfated polysaccharides covalently attached to a protein core is the heparan sulfate proteoglycan (HSPG) family of proteins. A few HSPGs were purified to homogeneity, including the large extra-  
 5 cellular matrix HSPG perlecan, the membrane associated glypicans and the integral membrane syndecans. The syndecans share a similar structure that includes a short highly conserved intracellular carboxy-terminal region, a single membrane-spanning domain and an extracellular domain with three to five possible attachment sites for glycosaminoglycans.

#### 10 Natural Cytotoxic Receptors

The terms "NKp46", "NKp30" and "NKp44" refer to the known natural cytotoxicity receptors expressed on NK cells preferably human which is capable of mediating direct killing of tumor and virus-infected cells.

The human NKp46 receptor has multiple isoforms including the currently known  
 15 isoforms: Isoform a (Accession No CAA04714; SEQ ID NO:6); Isoform b (Accession No. CAA06872; SEQ ID NO:7) Isoform c (Accession No. CAA06873; SEQ ID NO:8) Isoform d (Accession No. CAA06874; SEQ ID NO:9). In general the NKp46 receptor comprises two extracellular Ig-like domains of the C2 type (D1 and D2), a transmembrane portion and an intracellular segment. The extracellular portion of  
 20 NKp46 comprises a D1 domain, designated NKp46D1 (comprising residues 22-120 of the mature full length protein of isoform a) and a D2 domain, designated NKp46D2, comprising 134 amino acid residues (residues 121-254 of the full length receptor of isoform a).

The human NKp30 receptor (accession number AAH52582; SEQ ID NO:13)  
 25 comprises one extracellular immunoglobulin (Ig) like domain (residues 31-108)

The human NKp44 receptor (accession number CAB39168 SEQ ID NO:15) comprises one extracellular Ig domain designated herein NKp44D (residues 31-130 of the full length receptor). NKp44DL refers to the Ig-like domain and the NKp44DS refers to the hinge peptide connecting the extracellular domain to the membrane.

30 The term "cytotoxic effect" refers to a killing of target cells by any of a variety of biological, biochemical, or biophysical mechanisms. Cytolysis refers more specifically

to activity in which the effector lyses the plasma membrane of the target cell, thereby destroying its physical integrity. This results in the killing of the target cell.

The term "specific binding" as used herein refers to the preferential association of a molecule with a cell or tissue bearing a particular target molecule or marker and not to  
5 cells or tissues lacking that target molecule or expressing that target molecule at low levels. It is, of course, recognized that a certain degree of non-specific interaction may occur between a molecule and a non-target cell or tissue.

The term "conjugate" refers to a polypeptide formed by the joining of two or more polypeptides through a peptide bond formed between the amino terminus of one  
10 polypeptide and the carboxyl terminus of another polypeptide. The conjugate may be formed by the chemical coupling of the constituent polypeptides or it may be expressed as a single polypeptide fusion protein from a nucleic acid (polynucleotide) sequence encoding the single contiguous conjugate.

The term "active fragments" refers to "fragments", "variants", "analogs" or  
15 "derivatives" of the molecule. A "fragment" of a molecule, such as any of the nucleic acid or the amino acid sequence of the present invention is meant to refer to any nucleotide or amino acid subset of the molecule. A "variant" of such molecule is meant to refer to a naturally occurring molecule substantially similar to either the entire molecule or a fragment thereof. An "analog" of a molecule is a homologous molecule  
20 from the same species or from different species. The amino acid sequence of an analog or derivative may differ from the specific molecule, e.g. the NKp46, NKp30 or NKp44 receptors, used in the present invention when at least one residue is deleted, inserted or substituted.

The term "cellular ligand" refers generally to tumor cell membrane molecules  
25 capable of reacting with the target recognition segment of the peptide of the invention.

The term "target cells" refers to cells that are killed by the cytotoxic activity of the peptide of the invention. The target cells express the ligand for at least one of NKp46, NKp30 and NKp44 molecules and include, in particular, cells that are infected by a virus, cells that are malignant or otherwise derived from solid as well as non-solid  
30 tumors. The target cell is of mammalian origin.

The term "cell-mediated cytotoxicity or destruction" refers to antibody-dependent, cell-mediated cytotoxicity (ADCC) and natural killer (NK) cell killing.

Peptides, Peptidomimetics and Peptide Derivatives

Within the scope of the invention are included peptides, peptidomimetic and peptide analogs and peptide derivatives. The peptides to be used in the present invention may be prepared for example by the F-moc technique (52), or any other  
5 method of peptide synthesis known to those skilled in the art, such as for example by solid phase peptide synthesis. These fragments could also be produced by methods well known to one skilled in the art of biotechnology. For example, using a nucleic acid selected from the group including DNA, RNA, or cDNA. The desired fragments may be produced in live cell cultures and purified after cell harvesting as known in the art.

10 The term "amino acid" or "amino acids" is understood to include the 20 naturally occurring amino acids; those amino acids often modified post-translationally in vivo, including, for example, hydroxyproline, phosphoserine and phosphothreonine; and other unusual amino acids including, but not limited to, 2-aminoadipic acid, hydroxylysine, isodesmosine, nor-valine, nor-leucine and ornithine. Furthermore, the  
15 term "amino acid" includes both D- and L-amino acids.

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino  
20 acid polymers.

The present invention further comprises peptide derivatives and peptidomimetics. A peptide mimetic or peptidomimetic, is a molecule that mimics the biological activity of a peptide but is not completely peptidic in nature. Whether completely or partially non-peptide, peptidomimetics according to this invention provide a spatial arrangement  
25 of chemical moieties that closely resembles the three-dimensional arrangement of groups in the peptide on which the peptidomimetic is based. As a result of this similar active-site geometry, the peptidomimetic has effects on biological systems which are similar to the biological activity of the peptide.

Without wishing to be bound by theory, the present invention encompasses peptide,  
30 peptide analog and peptidomimetic compositions, in which the peptide, peptide analog and peptidomimetic are capable of binding to a membrane associated biomolecule of a tumor cell, the biomolecule comprising at least one sulfated polysaccharide. Said

peptide/peptidomimetic composition contributes to the treatment of any tumor cell, including solid and non-solid tumor cells. Said peptide/peptidomimetic compositions are effective in situations where targeting and lysing of a tumor cell is beneficial, including but not limited to proliferative diseases such as carcinomas of various tissues,  
5 melanomas, gliomas, lymphomas and the like.

Another aspect of the present invention encompasses peptide/peptidomimetic compositions capable of inhibiting tumor cell progression and proliferation.

There are clear advantages for using a mimetic of a given peptide rather than the peptide itself, because peptides commonly exhibit two undesirable properties: poor  
10 bioavailability and short duration of action. Peptide mimetics offer a route around these two major obstacles, since the molecules concerned have a long duration of action. Furthermore there are problems associated with stability, storage and immunoreactivity for peptides that are not experienced with peptide mimetics.

The design of the peptidomimetics may be based on the three-dimensional structure  
15 of the extracellular domain of NCR with or in complex with their ligands. Peptidomimetics are small molecules that can bind to ligands such as proteins and glycosaminoglycans by mimicking certain structural aspects of peptides and proteins. A primary goal in the design of peptide mimetics has been to reduce the susceptibility of mimics to cleavage and inactivation by peptidases, as described *supra*. Some  
20 techniques for preparing peptidomimetics are disclosed in US patents 5,550,251 and 5,288,707, for example. Non-limiting examples of the use of peptidomimetics in the art include anti-cancer drugs (US patent 5,965,539) inhibitors of p21 ras (US patent 5,910,478 ) and inhibitors of neurotrophin activity (US patent 6,291,247).

As contemplated by this invention, the term "peptide" includes modified forms of  
25 the peptide, so long as the modification does not alter the essential sequence and the modified peptide retains the ability to bind to a membrane-associated biomolecule of a tumor cell. Such modifications include amidation, N-terminal acetylation, glycosylation, biotinylation, etc. Particular modified versions of the L-amino acid peptides corresponding to the amino acid sequences SEQ ID NOS:1-5 are described  
30 below and are considered to be peptides according to this invention:

- a) Peptides with an N-Terminal D-Amino Acid: The presence of an N-terminal D-amino acid increases the serum stability of a peptide which otherwise contains L-

amino acids, because exopeptidases acting on the N-terminal residue cannot utilize a D-amino acid as a substrate. The amino acid sequences of the peptides with N-terminal D-amino acids are usually identical to the sequences of the amino acid peptides described above [e.g., SEQ ID NO:1-5], except that the N-terminal residue is a D-amino acid.

- 5
- b) Peptides with a C-Terminal D-Amino Acid: The presence of a C-terminal D-amino acid also stabilizes a peptide, which otherwise contains L-amino acids, for the same reason as in (a) above. Thus, the amino acid sequences of these peptides are usually identical to the sequences of the L-amino acid peptides described above [e.g., SEQ ID NO:1-5] except that the C-terminal residue is a D-amino acid.
- 10
- c) Cyclic Peptides: Cyclic peptides have no free N- or C-termini. Thus, they are not susceptible to proteolysis by exopeptidases, although they may be susceptible to endopeptidases, which do not cleave at peptide termini. The amino acid sequences of the cyclic peptides may be identical to the sequences of the L-amino acid peptides described above except that the topology is circular, rather than linear.
- 15
- d) Peptides with Substitution of Natural Amino Acids by Unnatural Amino Acids: Substitution of unnatural amino acids for natural amino acids can also confer resistance to proteolysis. Such a substitution can, for example, confer resistance to proteolysis by exopeptidases acting on the N-terminus. Such substitutions have been described (53) and these substitutions do not affect biological activity. Furthermore, the synthesis of peptides with unnatural amino acids is routine and known in the art (53).
- 20
- E. Peptides with N-Terminal or C-Terminal Chemical Groups: An effective approach to confer resistance to peptidases acting on the N-terminal or C-terminal residues of a peptide is to add chemical groups at the peptide termini, such that the modified peptide is no longer a substrate for the peptidase. One such chemical modification is glycosylation of the peptides at either or both termini. Certain chemical modifications, in particular N-terminal glycosylation, have been shown to increase the stability of peptides in human serum (54). Other chemical modifications which enhance serum stability include, but are not
- 25
- 30

limited to, the addition of an N-terminal alkyl group, consisting of a lower alkyl of from 1 to 20 carbons, such as an acetyl group, and/or the addition of a C-terminal amide or substituted amide group. Synthesis of N-substituted oligomers is disclosed in US patent 5,877,278.

- 5 F. Peptides with Additional Amino Acids: Also included within this invention are modified peptides which contain within their sequences the peptides described above. These longer peptide sequences, which result from the addition of extra amino acid residues are encompassed in this invention, since they have the same biological activity as the peptides described above.

10 Based on the available amino acid sequence of the extracellular domains of the different NCR, presented herein, the three-dimensional structure models of NKp46, NKp30, and NKp44 from X-ray crystal structure, commercially available software packages can be used to design small peptides and/or peptidomimetics, preferably non-hydrolyzable analogs, as specific antagonists/inhibitors.

15 Suitable commercially available software for analyzing crystal structure, designing and optimizing small peptides and peptidomimetics are well known to one with skill in the art.

The peptides of the present invention are peptides or peptide analogs having amino acid sequence derived from the NCR and peptidomimetics based on the structure of  
20 such peptides.

A preferred embodiment of the present invention is a peptidomimetic or a peptide fragment including 7 to 120 consecutive residues, preferably about 8 to about 100 residues, more preferably about 10 to about 50 residues having a sequence derived from the extracellular domain of the NCR encompassing the biomolecule binding site of the  
25 receptor. For NKp46, the currently preferred embodiments comprise a sequence derived from residues 153-175 (SEQ ID NO:1), or from residues 153-172 (SEQ ID NO:2) wherein the biomolecule comprises at least one sulfated polysaccharide. For other NCR preferred embodiments comprise an about 7 to about 120 residue peptidomimetic or a peptide fragment derived from: NKp30 residues 57-84 (SEQ ID  
30 NO: 3); NKp30 residues 57-76 (SEQ ID NO:4); NKp44 residues 51-74 (SEQ ID NO:5). (The amino acid residues according to the polypeptides that include the leader peptide).

The present invention further provides a method of identifying peptides derived from NCR which are capable of binding to a membrane-associated sulfated polysaccharide of a tumor cell, comprising the steps of:

- a. providing a set of candidate peptides;
- 5       b. contacting the peptides with the tumor cell;
- c. determining the binding of said peptides to said tumor cell; and
- d. isolating said bound peptides.

Candidate peptides may be selected stochastically from the sequence of the NCRs or using bioinformatics and or modeling techniques. The candidate peptides are generally prepared by recombinant methods or by peptide synthesis methods known in the art. Peptides of about 7 to about 120 amino acids are preferred. In one embodiment, the peptide is labeled with a reporter enzyme, isotopic label or fluorescence label. Binding of the peptides to the tumor cells and detection of binding may be performed by methods known in the art including, in a non-limiting example, direct and indirect methods such as ELISA.

#### Antibodies

The present invention further relates to an isolated antibody, preferably a monoclonal antibody which specifically binds to a molecule or structure comprising at least one sulfated polysaccharide in tumor cells and thus activates the NCR-dependent lysis of tumor cells. The isolated antibody of the invention can be coupled to any appropriate label for visualization purposes. Such labels include e.g. fluorescent labels, radioactive labels, enzymatic labels. The antibodies of the present invention are useful in diagnostic, therapeutic and imaging methods.

In another aspect, the present invention encompasses specific antibodies capable of blocking the binding of NK cells via their NCR to the membrane-associated target biomolecules in a tumor cell, thereby inhibiting NCR-dependent activity in autoimmunity. A preferred example is an antibody capable of binding to heparan sulfate-associated biomolecules which mediate NCR-dependent lysis.

The monoclonal antibodies (mAb) of the invention can be prepared using any technique that provides for the production of antibody molecules by cell lines in



culture. These include, but are not limited to, the original techniques of Köhler and Milstein, (55), modified as described in (56), the contents of which are hereby incorporated by reference.

Screening procedures that can be used to screen hybridoma cells producing  
5 antibodies, but are not limited to (1) enzyme-linked immunoadsorbent assays (ELISA), (2) immunoprecipitation or (3) fluorescent activated cell sorting (FACS) analyses. Many different types of ELISA that can be used to screen for the monoclonal antibodies can be envisioned by persons skilled in the art.

Once the desired hybridoma has been selected and cloned, the resultant antibody  
10 may be produced in one of two major ways. The purest monoclonal antibody is produced by in vitro culturing of the desired hybridoma in a suitable medium for a suitable length of time, followed by the recovery of the desired antibody from the supernatant. The length of time and medium are known or can readily be determined. This in vitro technique produces essentially monospecific monoclonal antibody,  
15 essentially free from other species of anti-human immunoglobulin. However, the in vitro method may not produce a sufficient quantity or concentration of antibody for some purposes, since the quantity of antibody generated is only about 50 µg/ml. To produce a much larger quantity of monoclonal antibody, the desired hybridoma may be injected into an animal, such as a mouse. preferably the mice are syngeneic or semi-  
20 syngeneic to the strain from which the monoclonal-antibody producing hybridomas were obtained. Injection of the hybridoma causes formation of antibody producing tumors after a suitable incubation time, which will result in a high concentration of the desired antibody (about 5-20 mg/ml) in the ascites of the host animal.

Antibody molecules can be purified by known techniques e.g. by  
25 immunoabsorption or immunoaffinity chromatography, chromatographic methods such as high performance liquid chromatography or a combination thereof.

In another aspect, the invention relates to isolated immuno-reactive fragments of the antibody of the invention. Such fragments notably include Fab, F(ab')<sub>2</sub>, and CDR antibody fragments. The skilled person will note that humanized antibodies of the  
30 invention can be derived therefrom as desired, notably when intended to be administered to a human person. By "immuno-reactive fragments of an antibody", it is meant any antibody fragment comprising the antigen binding-site.

Such fragments thus include F(ab')<sub>2</sub> fragments obtained either by enzymatic digestion of said antibody by proteolytic enzymes such as pepsin or papain, and Fab fragments derived thereof by reduction of the sulfhydryl groups located in the hinge regions, as known by any skilled person. Immunoreactive fragments can also comprise  
5 recombinant single chain or dimeric polypeptides whose sequence comprises the CDR regions of the antibody of interest. Isolated CDR regions themselves are also contemplated within the definition of the isolated immuno-reactive fragments of the invention.

Chimeric antibodies are molecules, the different portions of which are derived  
10 from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. Antibodies which have variable region framework residues substantially from human antibody (termed an acceptor antibody) and complementarity determining regions substantially from a mouse antibody (termed a donor antibody) are also referred to as humanized  
15 antibodies. Chimeric antibodies are primarily used to reduce immunogenicity in application and to increase yields in production, for example, where murine mAbs have higher yields from hybridomas but higher immunogenicity in humans, such that human/murine chimeric mAbs are used. Chimeric antibodies and methods for their production are known in the art (Better et al, 1988; Cabilly et al, 1984; Harlow et al,  
20 1988; Liu et al, 1987; Morrison et al, 1984; Boulianne et al, 1984; Neuberger et al, 1985; Sahagan et al, 1986; Sun et al, 1987; PCT patent applications WO 86/01533, WO 97/02671, WO 90/07861, WO 92/22653 and US patents 5,693,762, 5,693,761, 5,585,089, 5,530,101 and 5,225,539). These references are hereby incorporated by reference.

25 In addition to the conventional method of raising antibodies *in vivo*, antibodies can be generated *in vitro* using phage display technology. Such a production of recombinant antibodies is much faster compared to conventional antibody production and they can be generated against an enormous number of antigens. In contrast, in the conventional method, many antigens prove to be non-immunogenic or extremely toxic,  
30 and therefore cannot be used to generate antibodies in animals. Moreover, affinity maturation (i.e., increasing the affinity and specificity) of recombinant antibodies is very simple and relatively fast. Finally, large numbers of different antibodies against a specific antigen can be generated in one selection procedure. To generate recombinant

monoclonal antibodies one can use various methods all based on phage display libraries to generate a large pool of antibodies with different antigen recognition sites. Such a library can be made in several ways: One can generate a synthetic repertoire by cloning synthetic CDR3 regions in a pool of heavy chain germline genes and thus generating a large antibody repertoire, from which recombinant antibody fragments with various specificities can be selected. One can use the lymphocyte pool of humans as starting material for the construction of an antibody library. It is possible to construct naive repertoires of human IgM antibodies and thus create a human library of large diversity. This method has been widely used successfully to select a large number of antibodies against different antigens. Protocols for bacteriophage library construction and selection of recombinant antibodies are provided in the well-known reference text Current Protocols in Immunology, Colligan et al (Eds.), John Wiley & Sons, Inc. (1992-2000), Chapter 17, Section 17.1.

The present invention also relates to a method for the selective removal of tumor cells from a biological sample, which comprises the selective removal of those cells having at least one membrane-associated biomolecules comprising at least one sulfated polysaccharide. Such a method comprises contacting the biological sample with the isolated antibody of the present invention or the immunoreactive fragments thereof under condition appropriate for immune complex formation, and removing the immune complex thus formed.

According to various embodiments, a biological sample includes peripheral blood, plasma, bone marrow aspirates, lymphoid tissues, as well as cells isolated from cytappheresis, plasmapheresis and collection fluids such as synovial, cerebro-spinal, broncho-alveolar and peritoneal fluids.

## Pharmaceutical Compositions and Pharmacokinetics

The present invention is also directed to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least one peptide, peptide derivative or peptidomimetic of the present invention. The pharmaceutical composition will be administered according to known modes of peptide administration, including oral, intravenous, subcutaneous, intraarticular, intramuscular, inhalation, intranasal, intrathecal, intradermal, transdermal or other known routes. The dosage administered

will be dependent upon the age, sex, health condition and weight of the recipient, and the nature of the effect desired.

The composition of the invention further comprises a pharmaceutically acceptable diluent or carrier. The compositions according to the invention will in practice  
5 normally be administered orally or by injection. As used herein "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic  
10 composition is contemplated.

For oral administration tablets and capsules may contain conventional excipients, such as binders, for example syrup, sorbitol, or polyvinyl pyrrolidone; fillers, for example lactose, microcrystalline cellulose, corn starch, calcium phosphate or sorbitol; lubricants, for example magnesium stearate, stearic acid, polyethylene glycol or silica;  
15 disintegrates, for example potato starch or sodium starch glycolate, or surfactants, such as sodium lauryl sulphate. Oral liquid preparations can be in the form of for example water or oil suspensions, solutions, emulsions, syrups or elixirs, or can be supplied as a dry product for constitution with water or another suitable vehicle before use.

A composition according to the invention can be formulated for parenteral  
20 administration by injection or continuous infusion. Compositions for injection can be provided in unit dose form and can take a form such as suspension, solution or emulsion in oil or aqueous carriers and can contain formulating agents, such as suspending, stabilizing and/or dispersing agents. Alternatively, the active constituent can be present in powder form for constitution with a suitable carrier, for example  
25 sterile pyrogen-free water, before use. Intravenous administration, for example, is advantageous in the treatment of leukemias, lymphomas, and comparable malignancies of the lymphatic system. The composition of the invention may be administered directly into a body cavity adjacent to the location of a solid tumor, such as the intraperitoneal cavity, or injected directly into or adjacent to a solid tumor.

### 30 Methods of Treatment

It is proposed that the various methods and compositions of the invention will be broadly applicable to the treatment of any tumor cell, including solid and non-solid

tumor cells. Further provided is use of the compositions of the invention for the preparation of a medicament for the treatment of tumor cells and proliferative diseases. If the tissue is a part of the lymphatic or immune systems, malignant cells may include non-solid tumors of circulating cells. Malignancies of other tissues or organs may produce solid tumors. Exemplary solid tumors to which the present invention is directed include but are not limited to carcinomas of the lung, breast, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, prostate, thyroid, squamous cell carcinomas, adenocarcinomas, small cell carcinomas, melanomas, gliomas, neuroblastomas, and the like. Exemplary non-solid tumors to which the present invention is directed include but are not limited to B cell Lymphoma, T cell Lymphoma, or Leukemia such as Chronic Myelogenous Leukemia.

The following examples are presented in order to more fully illustrate certain embodiments of the invention. They should in no way, however, be construed as limiting the broad scope of the invention. One skilled in the art can readily devise many variations and modifications of the principles disclosed herein without departing from the scope of the invention.

### EXAMPLES

Cell Lines: The cell lines used herein were as follows:

PC-3: a human prostate adenocarcinoma derived from bone metastasis that is PSA negative and Androgen insensitive (ATCC no. CRL-1435).

1106: a human melanoma cell line that expresses no HLA-I antigens, established from a recurrent metastatic lesion (30).

HeLa: a human cervical adenocarcinoma (ATCC no. CCL-2).

EB-SP: EB murine T-lymphoma transfected with cDNA encoding for chimeric functional heparanase comprising human and chicken heparanase signal peptides (16).

PANC-1: human pancreatic ductal carcinoma (ATCC no. CRL-1469) over-expressing glypican-1 (31).

GAS6: PANC-1 cells stably transfected with full-length glypican-1 antisense construct, having reduced glypican-1 expression at both the RNA and protein levels;

Sham-PANC-1:control-transfected PANC-1 cells, high levels of glypican-1 (31).

Wild type CHO K1 cells and the mutant derivatives CHO pgsA-745 and CHO pgsD-677 were kindly supplied by Dr. Jeff Esko (32).

5 NK cells (lines and clones) were isolated from peripheral blood lymphocytes (PBL) using the human NK cell isolation kit and the autoMACS instrument (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). The NK cells were kept in culture as previously described (33).

#### Carbohydrates and proteoglycans

10 Glyc-PAAAs are carbohydrate complexes in which Glyc is the oligosaccharide part and PAA is a soluble polyacrylamide carrier of 30 kDa. The content of oligosaccharides in the conjugates is 20% mol. Thus, for LacNAc-PAA, on the average, each fifth unit of the PAA polymer is conjugated to LacNAc and the oligosaccharide content is 1.05  $\mu$ mol LacNAc/mg Glyc-PAA (17). A library of 35 different Glyc-PAAAs containing carbohydrate ligands for siglecs, galectins, selectins and others was used for  
15 initial screen and further identification. Low molecular weight (LMW) Heparin (H-3400), Heparan sulfate (H-9902), Hyaluronic acid (H-5388), Chondroitin sulfate A (C-8529) and Chondroitin sulfate C (C-4384) were purchased from Sigma (St. Louis, MO; 10 mg/ml). High molecular weight heparins that are modified in N-sulfation, O-sulfation and acetylation were described (18).

#### 20 Ig-fusion proteins

The generation of NKp30-Ig, NKp46-Ig, CD99-Ig and LIR1-Ig fusion protein was previously described (32, 19, 10). To generate the NKp46D2-Ig truncated fusion protein in COS cells, residues 101-235 (D2) of the mature NKp46 protein were PCR amplified, and the PCR-generated fragment was cloned into a mammalian expression  
25 vector containing the Fc portion of human IgG1, as previously described (34). In order to allow expression of NKp46D2-Ig, which lacks its original leader peptide sequence, a methionine start codon was added and cloned in tandem to the PCR-amplified fragment of NKp46D2 and in frame with the leader peptide of the CD5 antigen (accession number NP\_055022).

30 The sequences for the truncated fusion proteins, NKp44D-Ig (residues 1-111) was amplified by PCR from the NKp44-Ig-encoding plasmid and the corresponding PCR

fragments, containing kozak sequence and leader sequence of CD5, were cloned back into the pcDNA 3.1-Ig vector. Sequencing of the construct revealed that all cDNAs were in frame with the human Fc genomic DNA and were identical to the reported sequences. COS-7 cells were transiently transfected with the construct using  
5 FuGENE6® reagent (Roche Molecular Biochemicals, Indianapolis, IN) according to the manufacturer's instructions, and supernatants were collected and purified on a protein G column. SDS-PAGE analysis revealed that all Ig fusion proteins were approximately 95% pure and had the proper molecular mass.

For the production of NKp30-Ig and NKp46D2-Ig in CHO cells, the corresponding  
10 PCR fragments containing kozak sequence and leader sequence of CD5 were cloned into pcDNA 3.1-Ig vector. CHO cells were transfected with these expression vectors and G418-selected clones were screened for highest protein production. Re-cloned high producer clones were grown in CHO-SFM II medium (Gibco-BRL, Paisley, UK) and supernatants were collected daily and purified on protein-G columns using FPLC.

15 The conjugated proteins and their corresponding polynucleotides are referred to herein as follows:

SEQ ID NO:10 protein conjugate comprising NKp46 D1 and D2 domains fused to the Fc domain of an Ig;

SEQ ID NO:20 DNA encoding protein conjugate having SEQ ID NO:10;

20 SEQ ID NO:11 protein conjugate comprising CD5 leader sequence and NKp46 D1 domain fused to Fc domain;

SEQ ID NO:21 DNA encoding protein conjugate having SEQ ID NO:11;

SEQ ID NO:12 protein conjugate comprising CD5 leader sequence and NKp46 D2 domain fused to Fc domain;

25 SEQ ID NO:22 DNA encoding protein conjugate having SEQ ID NO:12;

SEQ ID NO:14 protein conjugate comprising CD5 leader sequence and NKp30 D domain fused to Fc domain;

SEQ ID NO:24 DNA encoding protein conjugate having SEQ ID NO:14;

30 SEQ ID NO:16 protein conjugate comprising CD5 leader sequence and NKp44 DS and DL domains fused to Fc domain;

SEQ ID NO:26 DNA encoding protein conjugate having SEQ ID NO:16;

SEQ ID NO:17 protein conjugate comprising CD5 leader sequence and NKp44 DL domain fused to Fc domain;

SEQ ID NO:27 DNA encoding protein conjugate having SEQ ID NO:17;

5 SEQ ID NO:18 protein conjugate comprising CD5 leader sequence and NKp44 DS domain fused to Fc domain;

SEQ ID NO:28 DNA encoding protein conjugate having SEQ ID NO:18.

#### Flow cytometry and antibodies

Cells were incubated with the various fusion-Igs for 2 h at 4°C, washed and stained  
10 with FITC-conjugated-F(ab')<sub>2</sub>-Goat-anti-human-IgG-Fcγ (109-096-098, Jackson ImmunoResearch, West Grove, PA). Staining and washing buffer consisted of 0.5% (w/v) BSA and 0.05% sodium azide in PBS. Staining of CHO and mutant CHO cells was carried out with 2% FCS instead of bovine serum albumin (BSA) in the different buffers. Propidium iodide (PI) was added prior to reading for exclusion of dead cells.  
15 Flow cytometry was performed using a FACSCalibur flow cytometer (Becton Dickinson, Mountain View, CA). Data files were acquired and analyzed using BD CELLQuest™ 3.3 software.

For most binding inhibition experiments, 20 µg of fusion-Ig were premixed with the GAG and added to cells for staining as above. In all experiments, each sample was  
20 stained twice in different wells. When results are presented as MFI (median fluorescence intensity), average MFI±SD of the duplicate staining is shown to reveal consistency of staining procedure. Human IgG1 (hIgG1 kappa, PHP010) was purchased from Serotec, Oxford, UK. Staining with the anti-heparin/heparan sulfate antibody HS4E4 was previously described (35).

#### 25 Glycosidases and treatment of cells

Tumor cells (10<sup>6</sup>) were washed twice in PBS, resuspended in 1ml reaction buffer alone (mock) or reaction buffer containing one of the following GAG-degrading enzymes (Sigma): keratanase (0.94 u/ml, K-2876), heparin lyase I (1.56 u/ml, H-2519) and heparin lyase III (1.25 u/ml, H-8891). Reaction buffer consisted of 1% (w/v) BSA,



1 µg/ml leupeptin and 10 u/ml aprotinin in PBS. Cells were incubated with enzyme for 60 min at 37°C, washed two times with PBS and stained with fusion-Igs as above.

#### Cytotoxicity assays

The cytotoxic activity of NK lines against the various targets was assessed in 5-hr 35S-release assays and in 4-hr Eu release time-resolved fluorescence assays, as previously described (20). In experiments where carbohydrates were included, NK cells were first mixed with the carbohydrates and then added to target cells. In all experiments shown the spontaneous release was less than 25% of maximal release. Each point represents the average of duplicate / triplicate values. The range of the duplicates / triplicates was within 5% of their mean.

#### Example 1: Binding of NKp46D2-Ig and NKp30-Ig to tumor cells is inhibited by N-acetylglucosamine

To study the effect of glycosylation on the binding of NKp46D2-Ig and NKp30-Ig to tumor cells, a library of 35 different polyacrylamide-glycoconjugates (Glyc-PAAAs) containing carbohydrate ligands for siglecs, galectins, selectins and others were screened. Glyc-PAAAs were mixed with Ig-fusion proteins, and staining of tumor cells with the Ig-fusion protein was measured. One Glyc-PAA, in which the saccharide moiety was 6-O-sulfo-LacNAc, inhibited binding of NKp46D2-Ig to HeLa cells (Fig. 1A). Similarly, the binding of NKp30-Ig was inhibited but not the positive binding of LIR1-Ig (Fig. 1A). Similar phenotype was observed when other tumor cell lines, 1106 melanoma and PC-3 prostate cancer, were assessed (Fig. 1C). Pre-incubation of the cells with 6-O-sulfo-LacNAc-PAA, followed by wash and application of the fusion proteins did not affect the binding. The contribution of the different glucose modifications to the inhibition of binding was further analyzed. Figures 1B, C show that removal of either the sulfate, acetyl or both from the N-acetylglucosamine abolished the effect on binding of NKp46D2-Ig to HeLa And PC-3 cells. Similar results were obtained for NKp30-Ig.

The effect of sulfation of galactose in LacNAc-PAA on the binding of Ig-fusion proteins was further studied. 3'-O-sulfo-LacNAc and 4',6'-di-O-sulfo-LacNAc did not inhibit binding of NKp46D2-Ig or NKp30-Ig, while 6'-O-sulfo-LacNAc manifested inconsistent inhibition phenotype of up to 25% reduction in binding.

To summarize, cell membrane-associated oligosaccharides appear to be involved in the binding of NKp46D2-Ig and NKp30-Ig to their cellular ligands, and 6O-sulfo-N-acetylglucoamine appears to be one of the building stones of these oligosaccharides.

Example 2: Binding of NCR-Igs to tumor cells is inhibited by heparin/heparan sulfate:

5 O-sulfation and acetylation are involved

The nature of the sulfated saccharide involved in binding of NKp46D2-Ig and NKp30-Ig to tumor cells was further evaluated by determining the possible role for glycosaminoglycans (GAGs). HeLa cells were incubated with mix of low molecular weight (LMW) heparin (10 µg/ml; white bar) and either NKp46D2-Ig, NKp30-Ig or  
10 LIR1-Ig. All 3 fusion proteins bound well to HeLa cells and heparin inhibited the binding of NKp46D2-Ig and NKp30-Ig, but not the binding of LIR1-Ig (Fig. 2A). Chondroitin A (gray bar) did not inhibit the binding of either of the 3 fusion proteins (Fig. 2A). Pre-incubation of the cells with LMW heparin, followed by wash and application of the fusion proteins did not affect the binding (data not shown).

15 The specific role of heparin/heparan sulfate in inhibition of NKp46D2-Ig binding to HeLa and PC-3 tumor cells is further shown in Figures 2B and 2C. Incremental concentrations of chondroitin A, chondroitin C and hyaluronic acid up to 10 µg/ml did not inhibit binding of NKp46D2-Ig. In contrast, heparin LMW and heparan sulfate in concentrations of 0.1 µg/ml inhibit binding of these fusion proteins. Similar results  
20 were obtained for NKp30-Ig.

The influence of variations in sulfation and acetylation of heparin on its capacity to inhibit the binding of NKp46D2-Ig and NKp30-Ig to tumor cells was examined. N-desulfation of heparin resulted in the removal 100% of the N-sulfate groups while O-desulfation removed 99% of the O-linked sulfates (18). N-desulfated  
25 heparin was a potent inhibitor of NKp46D2-Ig binding while O-desulfation of heparin reduced significantly the observed inhibition (Fig. 2D). Deacetylated heparin in which all N-acetyl groups were replaced by N-hexanoyl was then tested. This modification also reduced the potential of the heparin to inhibit binding of NKp46D2-Ig (Fig. 2D). Similar results were obtained for NKp30-Ig.

30 Similar inhibition results were shown for the heparin/heparan sulfate dependent binding of NKp44-Ig and NKp44D-Ig to tumor cells (Figures 3A-3C). Twenty µg fusion-Ig were premixed with different GAGs and  $10^5$  cells were then added for 2 h,

4°C. The heparan sulfate concentration was approximately 0.3  $\mu$ M. After incubation, cells were washed and incubated with FITC-anti-Fc second antibody. PI was added to exclude dead cells. Figures 3A1, A2 and A3 show staining of HeLa cells with NKp44-Ig, NKp44D-Ig and LIR1-Ig, respectively (primary FACS histogram overlays).

5        Figures 3B and 3C show the effect of titrated concentration of different GAGs (10  $\mu$ g/ml; □LMW heparin; ■chondroitin C; ♦hyaluronic acid; ○heparin sulfate; ▲chondroitin A) on NKp44-Ig binding. Binding to HeLa (Figure 3B) and PC-3 (Figure 3C). Results are presented as percentage of binding as compared to binding to cells with NKp44-Ig alone without premixing with a GAG. Results are from one  
10        representative experiment of two performed. In panels 3B and 3C, results are the average of 2 samples assayed in the same experiment. Bars,  $\pm$  SD.

### Example 3: NCR-Igs bind to heparan sulfate on tumor cells

The involvement of cell membrane-associated GAGs in the binding of NKp46D2-Ig and NKp30-Ig to their cellular ligands was examined. 6-O-sulfo-N-  
15        acetylglucosamine is a component of keratan sulfate and heparin/heparan sulfate but not of chondroitin sulfate and dermatan sulfate. Therefore, tumor cells were treated with (i) heparin lyase III (white bars) that efficiently degrades heparan sulfate and with  
20        a broad specificity, and (ii) heparin lyase I (light gray bars) that is selective in cleaving highly sulfated heparan sulfate. Yet, they do not degrade keratan sulfate and  
25        chondroitin sulfates A-E (21). Tumor cells were also treated with keratanase (dark gray bars) that efficiently degrade keratan sulfate but not other GAGs. Treatment of HeLa and 1106 melanoma cells with heparin lyase I or III, but not with keratanase, reduced the binding of NKp46D2-Ig and NKp30-Ig by 60 to 70% (Fig. 4A, 4B). LIR1-Ig did not bind to 1106 melanoma cells, thus the specificity of heparin lyase treatment on  
30        binding of LIR1-Ig to HeLa cells was studied. Both heparin lyase I and III treatments did not reduce the binding of LIR1-Ig to HeLa cells (Fig. 4A). Heparan sulfates are attached to the core protein primarily by O-linked glycoside bonds while keratan sulfates are attached primarily by N-linked bonds (22). In accordance, treatment of tumor cells with a blocker of O-glycosylation,  $\alpha$ benzyl-GalNAc, significantly reduced the binding of NKp30-Ig and NKp46D2-Ig.

The EB T lymphoma cell line and EB-SP cells that express a functional heparanase on the cell surface (16) were stained with NKp46D2-Ig. Staining of EB-SP was reduced

by 50% as compared to parental EB or EB-mock transfected (Fig. 4C) and staining with NKp30-Ig revealed the same phenotype. Therefore, results indicate that NKp46D2-Ig and NKp30-Ig bind to cell membrane-associated heparan sulfate. An alternative interpretation is that the binding is to a cell-surface molecule associated with heparan sulfate. Yet, this possibility is excluded by the observation that soluble heparan sulfate directly inhibits the binding of NKp46D2-Ig and NKp30-Ig to tumor cells (Fig. 2).

Membrane-associated heparan sulfate proteoglycans (HSPGs) can be divided into two families: glypicans, which are attached to the plasma membrane via glycosylphosphatidylinositol (GPI) anchors, and syndecans, which are transmembrane proteins (23). The involvement of GPI-anchored proteins in the binding of NKp30-Ig and NKp46D2-Ig to tumor cells was examined. Treatment of cells with D-mannosamine (white bars) inhibits GPI-anchor formation. Figure 4D shows that such inhibition reduced binding of NKp30-Ig and NKp46D2-Ig by 2 and 4 fold, respectively. The combined results indicate the involvement of glypicans in the binding of NKp46D2-Ig and to a lesser extent, of NKp30-Ig.

Similarly, we showed the involvement of heparan sulfate on HSPGs expressed on tumor cells for the binding of NKp44-Ig (Figure 5). Figures 5B1 and 5B2 show staining of parental CHO-K1, heparan sulfate-negative and chondroitin sulfate-negative CHO cells (CHOpgsA-745) and heparan sulfate-negative and chondroitin sulfate high-positive CHO cells (CHO pgsD-677) by NKp44-Ig and human (h) second Ab (primary FACS histogram overlay), respectively. Figures 5B3 and 5B4 show staining of parental CHO-K1 and CHO pgsA-745 with HS4E4 (ref 35) and mouse (m) second antibody (Figures 5C1, 5C2, 5C3). Staining of Sham and GAS-6 cells with NKp44-Ig, HS4E4 and hIgG1, respectively (primary FACS histogram overlay). Results are from one representative experiment of two performed. For all panels, MFI results are the average of 2 different samples assayed in the same experiment. Bars,  $\pm$  SD.

#### Example 4: Effect of 6-O-sulfo-N-acetylglucosamine-PAA and heparan sulfate on NK cytotoxicity

To test the role of NKp46 and NKp30 recognition of carbohydrates in NK lysis, the lysis of HeLa cells by NKs in the presence of Glyc-PAA was studied. Presence of 6-O-sulfo-LacNAc-PAA (black bars), but not LacNAc-PAA (white bars), reduced the lysis of HeLa cells by two fold (Fig. 6A). HeLa cell lysis by NK is mediated by NKp46 since

specific anti-NKp46 serum, produced as described (9), reduced HeLa lysis by two fold. A concentration 0.9mM 6-O-sulfo-LacNAc caused significant reduction of lysis (Fig. 6A). This is in the concentration range that reduced binding of NKp46D2-Ig and NKp30-Ig to HeLa and other tumor cells (Fig. 1). However, when heparin LMW was  
5 applied in order to block NK lysis, a significant two fold reduction in lysis of HeLa cells by NK was observed only at concentrations of 100 µg/ml and above (data not shown). This result is in agreement with previous publications on heparin-mediated inhibition of NK lysis (24, 25). Contrary to 6-O-sulfo-LacNAc-PAA, the heparin concentration needed for significant inhibition of lysis is at least 10 to about 1000 fold  
10 higher than the concentration used for inhibiting the binding of NKp30-Ig and NKp46D2-Ig (Figures 2 and 3). A possible explanation is the plurality of heparin functions that can augment cytotoxicity while masking NKp30 and NKp46. For example, heparin efficiently potentiates the lytic activity of perforin (26). Indeed, opposite effects of heparin on NK activity, which are time and concentration  
15 dependent, were reported by Wasik and Gorski (25). Hence, a concentration-dependent balance between lysis augmenting activities of heparin and masking of NKp30 and NKp46 can result in suppression of lysis in relatively high concentrations of heparin.

Therefore, to better study the effect of target membrane-associated HSPGs on lysis by NK, the lysis of EB and EB-SP by NK cells was compared. EB-SP lysis by NK cells  
20 was reduced by 2 fold as compared to parental EB (black bars) or EB-mock cells (gray bars) (Fig. 6B). Thus, reduction in binding of NKp46-D2-Ig and NKp30-Ig to tumor cells expressing cell-surface functional heparanase is correlated with the reduced lysis of these cells by NK (Figures 4C and 6B).

To further test the role of NKp46 and NKp30 recognition of carbohydrates in NK  
25 lysis, the lysis of CHO mutants lacking HSPG was examined. As shown in Figure 7A, the binding of NKp46 and NKp30 to the mutant CHO cells is significantly reduced as compared to wt CHO cells. Furthermore, the lysis of CHO mutant cells lacking HSPG by NK cells is significantly lower than the lysis of the wt CHO cells (Figure 7B). Thus, reduction in binding of NKp46-D2-Ig and NKp30-Ig to tumor cells lacking HSPG is  
30 correlated with reduced lysis of these cells by NK cells.

Example 5: Identification of a region in the NKp46D2 domain necessary for heparan sulfate/heparin binding

An attempt was made to identify the amino acid residues in NKp46 that are involved in heparin/heparan sulfate binding. Heparin and to a lesser extent, heparan sulfate, are negatively charged biological macromolecules due to the high content of negatively charged sulfo and carboxyl groups. Therefore, a region with a high positive surface potential could be a candidate for heparin/heparan sulfate binding. The electrostatic potential was calculated for NKp46 structure (1oll PDB code) using Delphi (36) and was presented on the surface using GRASP (37). A continuous region with a positive potential was detected on the surface of D2 domain, and is mainly donated by residues Lys 157, Arg 160, His 163, Arg 166 and Lys 170 (Figure 8). These residues reside on  $\beta$  strands C and C', on the loop that connect these strands and on the loop that connects C' strand and  $\beta$  strand E (38). These results are in agreement with the fact that only D2 is essential for binding NKp46 heparin/heparan sulfate (39).

The assumption that this patch, having a positive potential, may be involved in heparin/heparin sulfate binding was further supported by additional data. The high folding similarity of NKp46 and the killer inhibitory receptors (KIR2LD1, KIR2LD2, KIR2LD3 with 1im9, 1efx and 1b6u PDB codes, respectively) has been demonstrated (38). However, running the sequence of NKp46 on the 3DPSSM threading server (40) revealed a significant sequence identity of NKp46 to that of inhibitory receptor for human natural killer cells (P58-C152 Kir) (PDB code:1nkr). This protein appears as a member of the fibronectin type III super family. Further investigating of other members in this superfamily revealed a structure of human fibronectin (FN) type III repeats 12-14 that contain two heparin binding sites (PDB code: 1fnh). The first is a primary site (HBS-1) located in FN13, and the second is a putative secondary binding site (HBS-2) which is  $\sim 60\text{\AA}$  away in FN14 (41). HBS-1 appears in the structure as a continuous positively charged patch. The involvement of its residues in heparin binding was demonstrated by biochemical and mutagenesis data (42; 43; 44) and was further supported by the fact that these residues are conserved in FNs from frog to man (45; 46; 47). The existence of a secondary heparin-binding site (HBS-2) is suggested since biochemical data indicates that both FN13 and FN14 are essential for full binding of heparin (42; 43). Specific peptides that contain part of HBS-2 residues show heparin

binding ability (48; 49; 50; 51). In the crystal structure of FN12-14, HBS-2 appears as a positively charged region. This putative combining site consists of a cluster of basic residues Lys 216, Lys 219, Arg 225, Arg230 and Lys 261.

Superimposition of NKp46D2 with the FN13 structure shows no spatial overlap  
5 between HBS-1 and the residues that generate the region with the positive potential in NKp46. However, superimposition of NKp46D2 with FN14 reveals a nice spatial fit between HBS-2 and those residues that generate the region with the positive potential in NKp46 (Figure 9). In addition to the general structural resemblance of these two regions (3.6Å rmsd for C $\alpha$  of residues 212-233 and 153-169 of FN14 and NKp46,  
10 respectively) the side chains of Arg 160, His 163 and Arg 166 of NKp46 reside very close to side chains of Lys 219, Arg 225 and Arg 230 of FN14, respectively. Within these regions resides the positively charged Lys 157 of the NKp46 and Lys 216 of the FN14, located at the same 3 aa distance from the Arg 160 and Lys 219, respectively. Yet, Lys 170 of NKp46, proposed to be involved in the interaction based on the  
15 electrostatic potential map (Figure 8), does not fit with the FN14's Lys 261 (Figs 8, 9).

Based on the observations described above, certain site-directed mutations were made in NKp46D2 (Lys 157, Arg 160, His 163 and Arg 166; 4 point mutations) or (Lys 157, Arg 160, His 163, Arg 166, and Lys 170; 5 point mutations) into hydrophilic, neutral, amino acids with residues of similar size and to compare the ability of the  
20 mutant and the wild type receptors to bind heparin/heparan sulfate. Two constructs were prepared: Q4 (K157Q, R160Q, H163Q, and R166Q) and Q4T1 (K157Q, R160Q, H163Q, R166Q, and K170T). The mutated referred to herein as SEQ ID NO:29 SEQ ID NO:30.. Corresponding fusion proteins were prepared (NKp46D2-Q4-Ig and NKp46D2-Q4T1-Ig) and compared to NKp46D2-Ig. Figure 10 shows that NKp46D2-Ig, NKp46D2-Q4-Ig and NKp46D2-Q4T1-Ig bind similarly to IV-infected cells.  
25 However, binding of NKp46D2-Q4-Ig and NKp46D2-Q4T1-Ig to tumor cells is significantly reduced (in particular, NKp46D2-Q4T1-Ig) as compared to NKp46D2-Ig.

The corresponding peptide sequences of NKp30 and NKp44 having SEQ ID NOS:3-5 were determined based on the electrostatic map of the NKp30 and NKp44  
30 polypeptide and sequence comparison, and synthesized accordingly.

**REFERENCES**

1. Trinchieri, G. 1989. Biology of natural killer cells. *Adv Immunol* 47:187-376.
2. Long, E.O. 2002. Tumor cell recognition by natural killer cells. *Semin Cancer Biol* 12:57-61.
- 5     3. Biassoni, R., C. Cantoni, D. Pende, S. Sivori, S. Parolini, M. Vitale, C. Bottino, and A. Moretta. 2001. Human natural killer cell receptors and co-receptors. *Immunol Rev* 181:203-214.
4. Bakker, A.B., J. Wu, J.H. Phillips, and L.L. Lanier. 2000. NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. *Hum Immunol* 61:18-27.
- 10     5. Moretta, A., C. Bottino, M. Vitale, D. Pende, C. Cantoni, M.C. Mingari, R. Biassoni, and L. Moretta. 2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytotoxicity. *Annu Rev Immunol* 19:197-223.
6. Ljunggren, H.G., and K. Karre. 1990. In search of the 'missing self': MHC molecules and NK cell recognition. *Immunol Today* 11:237-244.
- 15     7. McQueen, K.L., and P. Parham. 2002. Variable receptors controlling activation and inhibition of NK cells. *Curr Opin Immunol* 14:615-621.
8. Mandelboim, O., and A. Porgador. 2001. NKp46. *Int J Biochem Cell Biol* 33:1147-1150.
- 20     9. Mandelboim, O., N. Lieberman, M. Lev, L. Paul, T.I. Arnon, Y. Bushkin, D.M. Davis, J.L. Strominger, J.W. Yewdell, and A. Porgador. 2001. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. *Nature* 409:1055-1060.
10. Arnon, T.I., M. Lev, G. Katz, Y. Chernobrov, A. Porgador, and O. Mandelboim. 2001. Recognition of viral hemagglutinins by NKp44 but not by NKp30. *Eur J Immunol* 31:2680-2689.
- 25     11. Lanier, L. L. and J. H. Phillips 1996 Inhibitory MHC class I receptors on NK cells and T cells. *Immunol. Today* 17:86-91.



12. Matsuda, K. et al. 2001. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. *Cancer Res* **61**, 5562-9.
13. Kleeff, J. et al. 1998. The cell-surface heparan sulfate proteoglycan glypican-1  
5 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. *J Clin Invest* **102**, 1662-73.
14. Sugahara, K. & Kitagawa, H. 2002. Heparin and heparan sulfate biosynthesis. *IUBMB Life* **54**, 163-75.
15. Miyamoto, K. et al. 2003. Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and  
10 pancreatic cancers. *Oncogene* **22**, 274-80.
16. Goldshmidt, O., E. Zcharia, R. Abramovitch, S. Metzger, H. Aingorn, Y. Friedmann, V. Schirmacher, E. Mitrani, and I. Vlodavsky. 2002. Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. *Proc Natl Acad Sci USA* **99**:10031-10036.  
15
17. Bovin, N.V. 1998. Polyacrylamide-based glycoconjugates as tools in glycobiology. *Glycoconj J* **15**:431-446.
18. Soker, S., D. Goldstaub, C.M. Svahn, I. Vlodavsky, B.Z. Levi, and G. Neufeld. 1994. Variations in the size and sulfation of heparin modulate the effect of  
20 heparin on the binding of VEGF165 to its receptors. *Biochem Biophys Res Commun* **203**:1339-1347.
19. Achdout, H., T.I. Arnon, G. Markel, T. Gonen-Gross, G. Katz, N. Lieberman, R. Gazit, A. Joseph, E. Kedar, and O. Mandelboim. 2003. Enhanced recognition of human NK receptors after influenza virus infection. *J Immunol* **171**:915-923.
20. Mandelboim, O., P. Malik, D.M. Davis, C.H. Jo, J.E. Boyson, and J.L. Strominger. 1999. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. *Proc Natl Acad Sci USA* **96**:5640-5644.  
25
21. Desai, U.R., H.M. Wang, and R.J. Linhardt. 1993. Specificity studies on the heparin lyases from *Flavobacterium heparinum*. *Biochemistry* **32**:8140-8145.

22. Sugahara, K., and H. Kitagawa. 2002. Heparin and heparan sulfate biosynthesis. *IUBMB Life* 54:163-175.
23. Bernfield, M., M. Gotte, P.W. Park, O. Reizes, M.L. Fitzgerald, J. Lincecum, and M. Zako. 1999. Functions of cell surface heparan sulfate proteoglycans. *Annu Rev Biochem* 68:729-777.
24. Yamamoto, H., S. Fuyama, S. Arai, and F. Sendo. 1985. Inhibition of mouse natural killer cytotoxicity by heparin. *Cell Immunol* 96:409-417.
25. Wasik, M., and A. Gorski. 1994. Heparin enhances generation of natural killer activity in vitro. *Arch Immunol Ther Exp (Warsz)* 42:73-76.
26. Ishiura, S., H. Koizumi, T. Tsukahara, and H. Sugita. 1988. Effects of heparin and other acid mucopolysaccharides on the activity of a cytolytic pore-forming protein (perforin) from cytotoxic T-lymphocytes. *J Biochem (Tokyo)* 103:11-13.
27. Kelley, L. A., MacCallum, R. M. & Sternberg, M. J. Enhanced genome annotation using structural profiles in the program 3D-PSSM. *J Mol Biol* 299, 499-520 (2000).
28. Sharma, A., Askari, J. A., Humphries, M. J., Jones, E. Y. & Stuart, D. I. 1999. Crystal structure of a heparin- and integrin-binding segment of human fibronectin. *Embo J* 18, 1468-79.
29. Capila, I., and R.J. Linhardt. 2002. Heparin-protein interactions. *Angew Chem Int Ed Engl* 41:391-412.
30. Porgador, A., O. Mandelboim, N. P. Restifo, and J. L. Strominger. 1997. Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. *Proc Natl Acad Sci USA* 94:13140.
31. Kleeff, J., S. Wildi, A. Kumbasar, H. Friess, A. D. Lander, and M. Korc. 1999. Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells. *Pancreas* 19:281.
32. Esko, J. D. 1991. Genetic analysis of proteoglycan structure, function and metabolism. *Curr Opin Cell Biol* 3:80.
33. Mandelboim, O., N. Lieberman, M. Lev, L. Paul, T. I. Arnon, Y. Bushkin, D. M. Davis, J. L. Strominger, J. W. Yewdell, and A. Porgador. 2001. Recognition of

- haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. *Nature* 409:1055.
34. Arnon, T. I., H. Achdout, N. Lieberman, R. Gazit, T. Gonen-Gross, G. Katz, A. Bar-Ilan, N. Bloushtain, M. Lev, A. Joseph, E. Kedar, A. Porgador, and O. Mandelboim. 2003. The mechanisms controlling the recognition of tumor and virus infected cells by NKp46. *Blood* 103(2):664-72.
35. Dennissen, M. A., G. J. Jenniskens, M. Pieffers, E. M. Versteeg, M. Petitou, J. H. Veerkamp, and T. H. van Kuppevelt. 2002. Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies. *J Biol Chem* 277:10982.
36. Nicholls, A., and Honig, B. 1991. A Rapid Finite Difference Algorithm, Utilizing Successive Over-Relaxation to Solve the Poisson-Boltzmann Equation. *J Comput Chem* 12:435-445.
37. Nicholls, A., Sharp, K. A., and Honig, B. 1991. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. *Proteins* 11:281-296.
38. Ponassi, M., Cantoni, C., Biassoni, R., Conte, R., Spallarossa, A., Pesce, A., Moretta, A., Moretta, L., Bolognesi, M., and Bordo, D. (2003) *Biochem Biophys Res Commun* 309:317-323.
39. Bloushtain-N., Qimron-U, Bar-Ilan-A, HersHKovitz-O, Fima-E, Korc-M., Vlodavsky-I, Bovin-NV, Porgador-A. 2004. Membrane-Associated Heparan Sulfate Proteoglycans are Involved in the Recognition of Cellular Targets by NKp30 and NKp46. *J. Immunology*. 173:2392-2401.
40. Kelley, L. A., MacCallum, R. M., and Sternberg, M. J. 2000. Enhanced genome annotation using structural profiles in the program 3D-PSSM. *J Mol Biol* 299:499-520.
41. Sharma, A., Askari, J. A., Humphries, M. J., Jones, E. Y., and Stuart, D. I. 1999. Crystal structure of a heparin- and integrin-binding segment of human fibronectin. *EMBO J* 18:1468-1479.

42. Ingham, K. C., S. A. Brew, and D. H. Atha. 1990. Interaction of heparin with fibronectin and isolated fibronectin domains. *Biochem. J.* 272:605-611.
43. Barkalow, F. J., and Schwarzbauer, J. E. 1991. Localization of the major heparin-binding site in fibronectin. *J Biol Chem* 266:7812-7818.
- 5 44. Busby, T. F., Argraves, W. S., Brew, S. A., Pechik, I., Gilliland, G. L., and Ingham, K. C. 1995. Heparin binding by fibronectin module III-13 involves six discontinuous basic residues brought together to form a cationic cradle. *J Biol Chem* 270:18558-18562.
- 10 45. Hynes, R. O., Schwarzbauer, J. E., and Tamkun, J. W. 1984. Fibronectin: a versatile gene for a versatile protein. *Ciba Found Symp* 108:75-92.
46. DeSimone, D. W., Spiegel, E., and Spiegel, M. 1985. The biochemical identification of fibronectin in the sea urchin embryo. *Biochem Biophys Res Commun* 133:183-188.
- 15 47. Norton, P. A., and Hynes, R. O. 1987. Alternative splicing of chicken fibronectin in embryos and in normal and transformed cells *Mol Cell Biol* 7:4297-4307.
48. McCarthy, J. B., Chelberg, M. K., Mickelson, D. J., and Furcht, L. T. 1988. Localization and chemical synthesis of fibronectin peptides with melanoma adhesion and heparin binding activities. *Biochemistry* 27:1380-1388.
- 20 49. McCarthy, J. B., Skubitz, A. P., Qi, Z., Yi, X. Y., Mickelson, D. J., Klein, D. J., and Furcht, L. T. 1990. RGD-independent cell adhesion to the carboxy-terminal heparin-binding fragment of fibronectin involves heparin-dependent and -independent activities. *J Cell Biol* 110:777-787.
- 25 50. Drake, S. L., Varnum, J., Mayo, K. H., Letourneau, P. C., Furcht, L. T., and McCarthy, J. B. 1993. Structural features of fibronectin synthetic peptide FN-C/H II, responsible for cell adhesion, neurite extension and heparan sulfate binding. *J Biol Chem* 268:15859-15867.
51. Woods, A., McCarthy, J. B., Furcht, L. T., and Couchman, J. R. 1993. A synthetic peptide from the COOH-terminal heparin-binding domain of fibronectin promotes focal adhesion formation. *Mol Biol Cell* 4:605-613.

52. Carpino, LA and Han, G.Y. 1972. The 9-fluorenylmethoxycarbonyl amino-protecting group. *J. Org. Chem* 37:3404-3409.
53. Collier, B.S., Springer, K.T., Scudder, L.E., Kutok, J.L., Ceruso, M., Prestwich G.D. 1993. Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and  
5 inactivation. *J Biol Chem.* 268(28):20741-3.
54. Powell, M.F., Stewart, T., Otvos, L. Jr, Urge, L., Gaeta, F.C., Sette, A., Arrhenius, T., Thomson, D., Soda, K., Colon, S.M. 1993. Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on  
10 peptide reactivity in human serum. *Pharm Res.* 10(9):1268-73.
55. Kohler, G., Milstein, C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 7;256(5517):495-7.
56. Anderson P, Blue ML, O'Brien C, Schlossman SF.1989. Monoclonal antibodies reactive with the T cell receptor zeta chain: production and characterization using  
15 a new method. *J Immunol.* 43(6):1899-904.

It will be appreciated by a person skilled in the art that the present invention is not limited by what has been particularly shown and described hereinabove. Rather, the scope of the invention is defined by the claims that follow.

**CLAIMS**




1. An isolated peptide fragment of a natural cytotoxicity receptor (NCR) of natural killer (NK) cells, active fragments, analogs or derivatives thereof, the peptide fragment capable of binding to a membrane-associated biomolecule of a tumor cell, the biomolecule comprising at least one sulfated polysaccharide, said biomolecule serving as the binding site of the NCR mediating the lysis of tumor cells by NK cells, with the proviso that said peptide is other than a full length NCR polypeptide or an isolated NCR extracellular domain.
2. The peptide fragment of claim 1 comprising about 7 to about 120 contiguous amino acids.
3. The peptide fragment of claim 1 comprising about 8 to about 100 contiguous amino acids.
4. The peptide fragment of claim 1 comprising less than about 50 contiguous amino acids.
5. The peptide of claim 1, wherein the peptide is a fragment of NCR selected from NKp44, NKp30 and NKp46.
6. The peptide of claim 5, wherein the peptide is a fragment of the D2 domain of NKp46 is selected from SEQ ID No:1 and SEQ ID No:2.
7. The peptide of claim 5, wherein said peptide is a fragment of NKp30 selected from SEQ ID No:3 and SEQ ID No:4.
8. The peptide of claim 5, wherein said peptide is a fragment of NKp44 having SEQ ID No: 5.
9. The peptide of claim 1, wherein said membrane-associated biomolecule is selected from a glycosaminoglycan and a proteoglycan.
10. The peptide of claim 9, wherein the glycosaminoglycan is selected from heparin, heparan sulfate and dermatan sulfate.
11. The peptide of claim 9, wherein the proteoglycan is heparan sulfate proteoglycan selected from a glypican and a syndecan.


12. A pharmaceutical composition comprising an isolated peptide fragment of a natural cytotoxicity receptor (NCR) of natural killer (NK) cells, active fragments, analogs or derivatives thereof, the peptide fragment capable of binding to a membrane-associated biomolecule of a tumor cell, the biomolecule comprising at least one sulfated polysaccharide, said biomolecule serving as the binding site of the NCR mediating the lysis of tumor cells by NK cells.
13. The pharmaceutical composition of claim 12, the isolated peptide fragment comprising about 7 to about 120 contiguous amino acids.
14. The pharmaceutical composition of claim 12, the isolated peptide fragment comprising about 8 to about 100 contiguous amino acids.
15. The pharmaceutical composition of claim 12, the isolated peptide fragment comprising less than about 50 contiguous amino acids.
16. The pharmaceutical composition of claim 12, wherein the peptide is a fragment of NCR selected from NKp44, NKp30 and NKp46.
17. The pharmaceutical composition of claim 16, wherein the peptide is a fragment of the D2 domain of NKp46 selected from SEQ ID No: 1 and SEQ ID No: 2.
18. The pharmaceutical composition of claim 16, wherein said peptide is a fragment of NKp30 selected from SEQ ID No: 3 and SEQ ID No: 4.
19. The pharmaceutical composition of claim 16, wherein said peptide is a fragment of NKp44 having SEQ ID No: 5.
20. The pharmaceutical composition of claim 12, wherein said membrane-associated biomolecule is selected from a glycosaminoglycan and a proteoglycan.
21. The pharmaceutical composition of claim 20, wherein the glycosaminoglycan is selected from heparin, heparan sulfate and dermatan sulfate.
22. The pharmaceutical composition of claim 20, wherein the proteoglycan is heparan sulfate proteoglycan selected from a glypican and a syndecan.




23. An antibody that recognizes an epitope on a target membrane-associated bio-molecule of a tumor cell, the biomolecule comprising at least one sulfated polysaccharide, said biomolecule mediating the lysis of tumor cells by NK cells via the natural cytotoxicity receptor (NCR).
- 5 24. The antibody of claim 23, wherein the membrane-associated biomolecule is selected from a glycosaminoglycan and a proteoglycan.
25. The antibody of claim 24, wherein the glycosaminoglycan is selected from heparin, heparan sulfate and dermatan sulfate.
- 10 26. The antibody of claim 24, wherein the proteoglycan is heparan sulfate proteoglycan selected from a glypican and a syndecan.
- 15 27. A pharmaceutical composition comprising an antibody that recognizes an epitope on a target membrane-associated bio-molecule of a tumor cell, the biomolecule comprising at least one sulfated polysaccharide, said biomolecule mediating the lysis of tumor cells by NK cells via the natural cytotoxicity receptor (NCR).
28. The pharmaceutical composition of claim 27, wherein the membrane-associated biomolecule is selected from a glycosaminoglycan and a proteoglycan.
- 20 29. The pharmaceutical composition of claim 28, wherein the glycosaminoglycan is selected from heparin, heparan sulfate and dermatan sulfate.
30. The pharmaceutical composition of claim 28, wherein the proteoglycan is heparan sulfate proteoglycan selected from a glypican and a syndecan
- 25 31. A method of targeting a tumor cell in a subject in need thereof via an NCR-dependent mechanism, said method comprising administering to the subject a pharmaceutical composition according to claims 12 or 27.
32. The method of claim 31, wherein the peptide is a fragment of NCR selected from NKp44, NKp30 and NKp46.
33. The method of claim 32, wherein the peptide is a fragment of the D2 domain of NKp46 is selected from SEQ ID No: 1 and SEQ ID NO:2



34. The method of claim 32, wherein the peptide is a fragment of NKp30 selected from a peptide having SEQ ID No. 3 and SEQ ID No. 4.
35. The method of claim 32, wherein the peptide is a fragment of NKp44 having SEQ ID No. 5.
- 5 36. The method of claim 32, wherein the membrane-associated bio-molecule is a glycosaminoglycan or a proteoglycan.
37. The method of claim 36, wherein the glycosaminoglycan is selected from heparin, heparan sulfate and dermatan sulfate.
38. The method of claim 36 wherein the proteoglycan is a heparan sulfate  
10 proteoglycan selected from a glypican and a syndecan.
39. A method of identifying peptides derived from NCR which are capable of binding to a membrane-associated sulfated polysaccharide of a tumor cell, comprising the steps of:
- a. providing a set of candidate peptides;
  - 15 b. contacting the peptides with a tumor cell;
  - c. determining the binding of said peptides to said tumor cell; and
  - d. isolating said bound peptides.
40. An antibody capable of blocking the binding of NK cells via NCR to  
20 membrane-associated sulfated polysaccharide bio-molecules in a cell, thereby inhibiting NCR-dependent cell lysis associated with autoimmunity.

**Figure 1A****Figure 1B****Figure 1C**

**Figure 2A**

**Figure 2B****Figure 2C****Figure 2D**





Figure 4B




Figure 4D




Figure 4A




Figure 4C












Figure 5A







LEGEND: CHO K1-wt  CHO pgsA-745 ..... CHO pgsD-677 \_\_\_\_



LEGEND:

Sham-PANC-1   
 GAS6 \_\_\_\_\_  
 Sham-PANC-1/ Second Ab .....  
 GAS6/Second Ab .....



**Figure 6A****Figure 6B**



**Figure 7A****Figure 7B**

Figure 8







Figure 9



**Figure 10A****Figure 10B**

## SEQUENCE LISTING

<110> Yissum Research Development Company of the Hebrew  
University of Jerusalem  
Ben-Gurion University of the Negev Research and  
Development Authority  
MANDELBOIM, Ofer  
PORGADOR, Angel

<120> PEPTIDES DERIVED FROM NATURAL CYTOTOXICITY RECEPTORS AND METHODS  
OF USE THEREOF

<130> NAP/003/PCT

<140> PCT/IL2004

<141> 2004-11-24

<150> US 60/524,648

<151> 2003-11-25

<160> 30

<170> PatentIn version 3.3

<210> 1

<211> 23

<212> PRT

<213> Homo sapiens

<220>

<221> PEPTIDE

<222> (1)..(23)

<223> amino acid residues 153-175 of human NKp46

<400> 1

Phe Leu Leu Leu Lys Glu Gly Arg Ser Ser His Val Gln Arg Gly Tyr  
1 5 10 15

Gly Lys Val Gln Ala Glu Phe  
20

<210> 2

<211> 20

<212> PRT

<213> homo sapiens

<220>

<221> PEPTIDE

<222> (1)..(20)

<223> aa 153-172 of NKp46 (SEQ ID NO:5 herein)

<220>

<221> PEPTIDE

<222> (1)..(20)

<223> aa residues 153-172 of human NKp46 (SEQ ID NO:5 herein)

<400> 2

Phe Leu Leu Leu Lys Glu Gly Arg Ser Ser His Val Gln Arg Gly Tyr  
1 5 10 15

Gly Lys Val Gln

20

<210> 3  
<211> 28  
<212> PRT  
<213> homo sapiens

<220>  
<221> PEPTIDE  
<222> (1)..(28)  
<223> derived from NKp30 amino acids 56-83

<220>  
<221> PEPTIDE  
<222> (1)..(28)  
<223> amino acid residues 57-84 derived from human NKp30

<400> 3

Arg Asp Glu Val Val Pro Gly Lys Glu Val Arg Asn Gly Thr Pro Glu  
1 5 10 15

Phe Arg Gly Arg Leu Ala Pro Leu Ala Ser Ser Arg  
20 25

<210> 4  
<211> 20  
<212> PRT  
<213> homo sapiens

<220>  
<221> PEPTIDE  
<222> (1)..(20)  
<223> corresponds to amino acids 56-75 of NKp30

<220>  
<221> PEPTIDE  
<222> (1)..(20)  
<223> amino acids residues 57-76 of human NKp30

<400> 4

Arg Asp Glu Val Val Pro Gly Lys Glu Val Arg Asn Gly Thr Pro Glu  
1 5 10 15

Phe Arg Gly Arg  
20

<210> 5  
<211> 24  
<212> PRT  
<213> homo sapiens

<220>  
<221> PEPTIDE  
<222> (1)..(24)  
<223> amino acids 61-80 of NKp44

<220>  
<221> PEPTIDE

&lt;222&gt; (1)..(24)

&lt;223&gt; amino acid residues 51-74 of human Nkp44

&lt;400&gt; 5

Lys Lys Gly Trp Cys Lys Glu Ala Ser Ala Leu Val Cys Ile Arg Leu  
 1 5 10 15

Val Thr Ser Ser Lys Pro Arg Thr  
 20

&lt;210&gt; 6

&lt;211&gt; 304

&lt;212&gt; PRT

&lt;213&gt; homo sapiens

&lt;300&gt;

&lt;308&gt; NCBI/CAA04714

&lt;309&gt; 1998-09-22

&lt;313&gt; (1)..(304)

&lt;400&gt; 6

Met Ser Ser Thr Leu Pro Ala Leu Leu Cys Val Gly Leu Cys Leu Ser  
 1 5 10 15

Gln Arg Ile Ser Ala Gln Gln Gln Thr Leu Pro Lys Pro Phe Ile Trp  
 20 25 30

Ala Glu Pro His Phe Met Val Pro Lys Glu Lys Gln Val Thr Ile Cys  
 35 40 45

Cys Gln Gly Asn Tyr Gly Ala Val Glu Tyr Gln Leu His Phe Glu Gly  
 50 55 60

Ser Leu Phe Ala Val Asp Arg Pro Lys Pro Pro Glu Arg Ile Asn Lys  
 65 70 75 80

Val Lys Phe Tyr Ile Pro Asp Met Asn Ser Arg Met Ala Gly Gln Tyr  
 85 90 95

Ser Cys Ile Tyr Arg Val Gly Glu Leu Trp Ser Glu Pro Ser Asn Leu  
 100 105 110

Leu Asp Leu Val Val Thr Glu Met Tyr Asp Thr Pro Thr Leu Ser Val  
 115 120 125

His Pro Gly Pro Glu Val Ile Ser Gly Glu Lys Val Thr Phe Tyr Cys  
 130 135 140

Arg Leu Asp Thr Ala Thr Ser Met Phe Leu Leu Lys Glu Gly Arg  
 145 150 155 160

Ser Ser His Val Gln Arg Gly Tyr Gly Lys Val Gln Ala Glu Phe Pro  
 165 170 175



Leu Gly Pro Val Thr Thr Ala His Arg Gly Thr Tyr Arg Cys Phe Gly  
180 185 190

Ser Tyr Asn Asn His Ala Trp Ser Phe Pro Ser Glu Pro Val Lys Leu  
195 200 205

Leu Val Thr Gly Asp Ile Glu Asn Thr Ser Leu Ala Pro Glu Asp Pro  
210 215 220

Thr Phe Pro Ala Asp Thr Trp Gly Thr Tyr Leu Leu Thr Thr Glu Thr  
225 230 235 240

Gly Leu Gln Lys Asp His Ala Leu Trp Asp His Thr Ala Gln Asn Leu  
245 250 255

Leu Arg Met Gly Leu Ala Phe Leu Val Leu Val Ala Leu Val Trp Phe  
260 265 270

Leu Val Glu Asp Trp Leu Ser Arg Lys Arg Thr Arg Glu Arg Ala Ser  
275 280 285

Arg Ala Ser Thr Trp Glu Gly Arg Arg Arg Leu Asn Thr Gln Thr Leu  
290 295 300

<210> 7  
<211> 287  
<212> PRT  
<213> homo sapiens

<300>  
<308> NCBI/CAA06872  
<309> 1998-09-22  
<313> (1)..(287)

<400> 7

Met Ser Ser Thr Leu Pro Ala Leu Leu Cys Val Gly Leu Cys Leu Ser  
1 5 10 15

Gln Arg Ile Ser Ala Gln Gln Gln Thr Leu Pro Lys Pro Phe Ile Trp  
20 25 30

Ala Glu Pro His Phe Met Val Pro Lys Glu Lys Gln Val Thr Ile Cys  
35 40 45

Cys Gln Gly Asn Tyr Gly Ala Val Glu Tyr Gln Leu His Phe Glu Gly  
50 55 60

Ser Leu Phe Ala Val Asp Arg Pro Lys Pro Pro Glu Arg Ile Asn Lys  
65 70 75 80

Val Lys Phe Tyr Ile Pro Asp Met Asn Ser Arg Met Ala Gly Gln Tyr  
85 90 95

Ser Cys Ile Tyr Arg Val Gly Glu Leu Trp Ser Glu Pro Ser Asn Leu  
100 105 110

Leu Asp Leu Val Val Thr Glu Met Tyr Asp Thr Pro Thr Leu Ser Val  
115 120 125

His Pro Gly Pro Glu Val Ile Ser Gly Glu Lys Val Thr Phe Tyr Cys  
130 135 140

Arg Leu Asp Thr Ala Thr Ser Met Phe Leu Leu Leu Lys Glu Gly Arg  
145 150 155 160

Ser Ser His Val Gln Arg Gly Tyr Gly Lys Val Gln Ala Glu Phe Pro  
165 170 175

Leu Gly Pro Val Thr Thr Ala His Arg Gly Thr Tyr Arg Cys Phe Gly  
180 185 190

Ser Tyr Asn Asn His Ala Trp Ser Phe Pro Ser Glu Pro Val Lys Leu  
195 200 205

Leu Val Thr Gly Asp Ile Glu Asn Thr Ser Leu Ala Pro Glu Asp Pro  
210 215 220

Thr Phe Pro Asp His Ala Leu Trp Asp His Thr Ala Gln Asn Leu Leu  
225 230 235 240

Arg Met Gly Leu Ala Phe Leu Val Leu Val Ala Leu Val Trp Phe Leu  
245 250 255

Val Glu Asp Trp Leu Ser Arg Lys Arg Thr Arg Glu Arg Ala Ser Arg  
260 265 270

Ala Ser Thr Trp Glu Gly Arg Arg Arg Leu Asn Thr Gln Thr Leu  
275 280 285

<210> 8  
<211> 209  
<212> PRT  
<213> homo sapiens

<300>  
<308> NCBI/CAA06873  
<309> 1998-09-22  
<313> (1)..(209)

<400> 8

Met Ser Ser Thr Leu Pro Ala Leu Leu Cys Val Gly Leu Cys Leu Ser  
1 5 10 15

Gln Arg Ile Ser Ala Gln Gln Gln Met Tyr Asp Thr Pro Thr Leu Ser  
20 25 30

Val His Pro Gly Pro Glu Val Ile Ser Gly Glu Lys Val Thr Phe Tyr  
35 40 45

Cys Arg Leu Asp Thr Ala Thr Ser Met Phe Leu Leu Leu Lys Glu Gly  
50 55 60

Arg Ser Ser His Val Gln Arg Gly Tyr Gly Lys Val Gln Ala Glu Phe  
65 70 75 80

Pro Leu Gly Pro Val Thr Thr Ala His Arg Gly Thr Tyr Arg Cys Phe  
85 90 95

Gly Ser Tyr Asn Asn His Ala Trp Ser Phe Pro Ser Glu Pro Val Lys  
100 105 110

Leu Leu Val Thr Gly Asp Ile Glu Asn Thr Ser Leu Ala Pro Glu Asp  
115 120 125

Pro Thr Phe Pro Ala Asp Thr Trp Gly Thr Tyr Leu Leu Thr Thr Glu  
130 135 140

Thr Gly Leu Gln Lys Asp His Ala Leu Trp Asp His Thr Ala Gln Asn  
145 150 155 160

Leu Leu Arg Met Gly Leu Ala Phe Leu Val Leu Val Ala Leu Val Trp  
165 170 175

Phe Leu Val Glu Asp Trp Leu Ser Arg Lys Arg Thr Arg Glu Arg Ala  
180 185 190

Ser Arg Ala Ser Thr Trp Glu Gly Arg Arg Arg Leu Asn Thr Gln Thr  
195 200 205

Leu

<210> 9  
<211> 192  
<212> PRT  
<213> homo sapiens

<300>  
<308> NCBI/CAA06874  
<309> 1998-09-22  
<313> (1)..(192)

<400> 9

Met Ser Ser Thr Leu Pro Ala Leu Leu Cys Val Gly Leu Cys Leu Ser  
1 5 10 15

Gln Arg Ile Ser Ala Gln Gln Gln Met Tyr Asp Thr Pro Thr Leu Ser  
20 25 30

Val His Pro Gly Pro Glu Val Ile Ser Gly Glu Lys Val Thr Phe Tyr  
35 40 45

Cys Arg Leu Asp Thr Ala Thr Ser Met Phe Leu Leu Leu Lys Glu Gly  
50 55 60

Arg Ser Ser His Val Gln Arg Gly Tyr Gly Lys Val Gln Ala Glu Phe  
65 70 75 80

Pro Leu Gly Pro Val Thr Thr Ala His Arg Gly Thr Tyr Arg Cys Phe  
85 90 95

Gly Ser Tyr Asn Asn His Ala Trp Ser Phe Pro Ser Glu Pro Val Lys  
100 105 110

Leu Leu Val Thr Gly Asp Ile Glu Asn Thr Ser Leu Ala Pro Glu Asp  
115 120 125

Pro Thr Phe Pro Asp His Ala Leu Trp Asp His Thr Ala Gln Asn Leu  
130 135 140

Leu Arg Met Gly Leu Ala Phe Leu Val Leu Val Ala Leu Val Trp Phe  
145 150 155 160

Leu Val Glu Asp Trp Leu Ser Arg Lys Arg Thr Arg Glu Arg Ala Ser  
165 170 175

Arg Ala Ser Thr Trp Glu Gly Arg Arg Arg Leu Asn Thr Gln Thr Leu  
180 185 190

<210> 10  
<211> 488  
<212> PRT  
<213> artificial

<220>  
<223> conjugate of leader peptide, D1 and D2 domains of NKp46 with Fc domain

<400> 10

Met Ser Ser Thr Leu Pro Ala Leu Leu Cys Val Gly Leu Cys Leu Ser  
1 5 10 15

Gln Arg Ile Ser Ala Gln Gln Gln Thr Leu Pro Lys Pro Phe Ile Trp  
20 25 30

Ala Glu Pro His Phe Met Val Pro Lys Glu Lys Gln Val Thr Ile Cys  
35 40 45

Cys Gln Gly Asn Tyr Gly Ala Val Glu Tyr Gln Leu His Phe Glu Gly  
50 55 60

Ser Leu Phe Ala Val Asp Arg Pro Lys Pro Pro Glu Arg Ile Asn Lys  
 65 70 75 80  
 Val Lys Phe Tyr Ile Pro Asp Met Asn Ser Arg Met Ala Gly Gln Tyr  
 85 90 95  
 Ser Cys Ile Tyr Arg Val Gly Glu Leu Trp Ser Glu Pro Ser Asn Leu  
 100 105 110  
 Leu Asp Leu Val Val Thr Glu Met Tyr Asp Thr Pro Thr Leu Ser Val  
 115 120 125  
 His Pro Gly Pro Glu Val Ile Ser Gly Glu Lys Val Thr Phe Tyr Cys  
 130 135 140  
 Arg Leu Asp Thr Ala Thr Ser Met Phe Leu Leu Lys Glu Gly Arg  
 145 150 155 160  
 Ser Ser His Val Gln Arg Gly Tyr Gly Lys Val Gln Ala Glu Phe Pro  
 165 170 175  
 Leu Gly Pro Val Thr Thr Ala His Arg Gly Thr Tyr Arg Cys Phe Gly  
 180 185 190  
 Ser Tyr Asn Asn His Ala Trp Ser Phe Pro Ser Glu Pro Val Lys Leu  
 195 200 205  
 Leu Val Thr Gly Asp Ile Glu Asn Thr Ser Leu Ala Pro Glu Asp Pro  
 210 215 220  
 Thr Phe Pro Ala Asp Thr Trp Gly Thr Tyr Leu Leu Thr Thr Glu Thr  
 225 230 235 240  
 Gly Leu Gln Lys Asp His Ala Leu Trp Asp His Thr Ala Gln Asp Pro  
 245 250 255  
 Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala  
 260 265 270  
 Pro Glu Phe Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro  
 275 280 285  
 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val  
 290 295 300  
 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val  
 305 310 315 320  
 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln  
 325 330 335

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln  
340 345 350

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala  
355 360 365

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro  
370 375 380

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr  
385 390 395 400

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser  
405 410 415

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr  
420 425 430

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr  
435 440 445

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe  
450 455 460

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys  
465 470 475 480

Ser Leu Ser Leu Ser Pro Gly Lys  
485

<210> 11  
<211> 364  
<212> PRT  
<213> artificial

<220>  
<223> conjugate of CD5 leader peptide and D1 of NKp46 with Fc domain

<400> 11

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu  
1 5 10 15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Gln  
20 25 30

Gln Gln Thr Leu Pro Lys Pro Phe Ile Trp Ala Glu Pro His Phe Met  
35 40 45

Val Pro Lys Glu Lys Gln Val Thr Ile Cys Cys Gln Gly Asn Tyr Gly  
50 55 60

Ala Val Glu Tyr Gln Leu His Phe Glu Gly Ser Leu Phe Ala Val Asp  
65 70 75 80

Arg Pro Lys Pro Pro Glu Arg Ile Asn Lys Val Lys Phe Tyr Ile Pro  
 85 90 95  
 Asp Met Asn Ser Arg Met Ala Gly Gln Tyr Ser Cys Ile Tyr Arg Val  
 100 105 110  
 Gly Glu Leu Trp Ser Glu Pro Ser Asn Leu Leu Asp Leu Val Val Thr  
 115 120 125  
 Glu Met Asp Pro Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro  
 130 135 140  
 Pro Cys Pro Ala Pro Glu Phe Glu Gly Ala Pro Ser Val Phe Leu Phe  
 145 150 155 160  
 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val  
 165 170 175  
 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe  
 180 185 190  
 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro  
 195 200 205  
 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr  
 210 215 220  
 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val  
 225 230 235 240  
 Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala  
 245 250 255  
 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg  
 260 265 270  
 Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly  
 275 280 285  
 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro  
 290 295 300  
 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser  
 305 310 315 320  
 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln  
 325 330 335  
 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His  
 340 345 350

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
 355 360

<210> 12

<211> 393

<212> PRT

<213> artificial

<220>

<223> conjugate of CD5 leader peptide and D2 domain of NKp46 with Fc domain

<400> 12

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu  
 1 5 10 15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Tyr  
 20 25 30

Asp Thr Pro Thr Leu Ser Val His Pro Gly Pro Glu Val Ile Ser Gly  
 35 40 45

Glu Lys Val Thr Phe Tyr Cys Arg Leu Asp Thr Ala Thr Ser Met Phe  
 50 55 60

Leu Leu Leu Lys Glu Gly Arg Ser Ser His Val Gln Arg Gly Tyr Gly  
 65 70 75 80

Lys Val Gln Ala Glu Phe Pro Leu Gly Pro Val Thr Thr Ala His Arg  
 85 90 95

Gly Thr Tyr Arg Cys Phe Gly Ser Tyr Asn Asn His Ala Trp Ser Phe  
 100 105 110

Pro Ser Glu Pro Val Lys Leu Leu Val Thr Gly Asp Ile Glu Asn Thr  
 115 120 125

Ser Leu Ala Pro Glu Asp Pro Thr Phe Pro Asp Thr Trp Gly Thr Tyr  
 130 135 140

Leu Leu Thr Thr Glu Thr Gly Leu Gln Lys Asp His Ala Leu Trp Asp  
 145 150 155 160

Pro Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro  
 165 170 175

Ala Pro Glu Phe Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys  
 180 185 190

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val  
 195 200 205



Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr  
210 215 220

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu  
225 230 235 240

Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His  
245 250 255

Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys  
260 265 270

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln  
275 280 285

Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu  
290 295 300

Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro  
305 310 315 320

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn  
325 330 335

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu  
340 345 350

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val  
355 360 365

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln  
370 375 380

Lys Ser Leu Ser Leu Ser Pro Gly Lys  
385 390

<210> 13  
<211> 201  
<212> PRT  
<213> homo sapiens

<300>  
<308> NCBI/AAH52582  
<309> 2004-06-30  
<313> (1)..(201)

<400> 13

Met Ala Trp Met Leu Leu Leu Ile Leu Ile Met Val His Pro Gly Ser  
1 5 10 15

Cys Ala Leu Trp Val Ser Gln Pro Pro Glu Ile Arg Thr Leu Glu Gly  
20 25 30

Ser Ser Ala Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu  
35 40 45

Ala Ile Gly Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys  
50 55 60

Glu Val Arg Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu  
65 70 75 80

Ala Ser Ser Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg  
85 90 95

Asp Val Arg Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val  
100 105 110

Leu Gly Leu Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu  
115 120 125

Lys Glu His Pro Gln Leu Gly Ala Gly Thr Val Leu Leu Leu Arg Ala  
130 135 140

Gly Phe Tyr Ala Val Ser Phe Leu Ser Val Ala Val Gly Ser Thr Val  
145 150 155 160

Tyr Tyr Gln Gly Lys Cys Leu Thr Trp Lys Gly Pro Arg Arg Gln Leu  
165 170 175

Pro Ala Val Val Pro Ala Pro Leu Pro Pro Pro Cys Gly Ser Ser Ala  
180 185 190

His Leu Leu Pro Pro Val Pro Gly Gly  
195 200

<210> 14

<211> 382

<212> PRT

<213> artificial

<220>

<223> conjugate of CD5 leader peptide and D (Ig-like) domain of Nkp30  
with Fc domain

<400> 14

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu  
1 5 10 15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Leu  
20 25 30

Trp Val Ser Gln Pro Leu Glu Ile Arg Thr Leu Glu Gly Ser Ser Ala  
35 40 45

Phe Leu Pro Cys Ser Phe Asn Ala Ser Gln Gly Arg Leu Ala Ile Gly  
 50 55 60  
 Ser Val Thr Trp Phe Arg Asp Glu Val Val Pro Gly Lys Glu Val Arg  
 65 70 75 80  
 Asn Gly Thr Pro Glu Phe Arg Gly Arg Leu Ala Pro Leu Ala Ser Ser  
 85 90 95  
 Arg Phe Leu His Asp His Gln Ala Glu Leu His Ile Arg Asp Val Arg  
 100 105 110  
 Gly His Asp Ala Ser Ile Tyr Val Cys Arg Val Glu Val Leu Gly Leu  
 115 120 125  
 Gly Val Gly Thr Gly Asn Gly Thr Arg Leu Val Val Glu Lys Glu His  
 130 135 140  
 Pro Gln Leu Gly Asp Pro Glu Pro Lys Ser Ser Asp Lys Thr His Thr  
 145 150 155 160  
 Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Ala Pro Ser Val Phe  
 165 170 175  
 Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro  
 180 185 190  
 Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val  
 195 200 205  
 Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr  
 210 215 220  
 Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val  
 225 230 235 240  
 Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys  
 245 250 255  
 Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser  
 260 265 270  
 Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro  
 275 280 285  
 Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val  
 290 295 300  
 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly  
 305 310 315 320

Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp  
 325 330 335

Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp  
 340 345 350

Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His  
 355 360 365

Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
 370 375 380

<210> 15  
 <211> 276  
 <212> PRT  
 <213> homo sapiens

<300>  
 <308> NCBI/CAB39168  
 <309> 1999-03-15  
 <313> (1)..(276)

<400> 15

Met Ala Trp Arg Ala Leu His Pro Leu Leu Leu Leu Leu Leu Phe  
 1 5 10 15

Pro Gly Ser Gln Ala Gln Ser Lys Ala Gln Val Leu Gln Ser Val Ala  
 20 25 30

Gly Gln Thr Leu Thr Val Arg Cys Gln Tyr Pro Pro Thr Gly Ser Leu  
 35 40 45

Tyr Glu Lys Lys Gly Trp Cys Lys Glu Ala Ser Ala Leu Val Cys Ile  
 50 55 60

Arg Leu Val Thr Ser Ser Lys Pro Arg Thr Met Ala Trp Thr Ser Arg  
 65 70 75 80

Phe Thr Ile Trp Asp Asp Pro Asp Ala Gly Phe Phe Thr Val Thr Met  
 85 90 95

Thr Asp Leu Arg Glu Glu Asp Ser Gly His Tyr Trp Cys Arg Ile Tyr  
 100 105 110

Arg Pro Ser Asp Asn Ser Val Ser Lys Ser Val Arg Phe Tyr Leu Val  
 115 120 125

Val Ser Pro Ala Ser Ala Ser Thr Gln Thr Pro Trp Thr Pro Arg Asp  
 130 135 140

Leu Val Ser Ser Gln Thr Gln Thr Gln Ser Cys Val Pro Pro Thr Ala  
 145 150 155 160

Gly Ala Arg Gln Ala Pro Glu Ser Pro Ser Thr Ile Pro Val Pro Ser  
165 170 175

Gln Pro Gln Asn Ser Thr Leu Arg Pro Gly Pro Ala Ala Pro Ile Ala  
180 185 190

Leu Val Pro Val Phe Cys Gly Leu Leu Val Ala Lys Ser Leu Val Leu  
195 200 205

Ser Ala Leu Leu Val Trp Trp Gly Asp Ile Trp Trp Lys Thr Val Met  
210 215 220

Glu Leu Arg Ser Leu Asp Thr Gln Lys Ala Thr Cys His Leu Gln Gln  
225 230 235 240

Val Thr Asp Leu Pro Trp Thr Ser Val Ser Ser Pro Val Glu Arg Glu  
245 250 255

Ile Leu Tyr His Thr Val Ala Arg Thr Lys Ile Ser Asp Asp Asp  
260 265 270

Glu His Thr Leu  
275

<210> 16  
<211> 434  
<212> PRT  
<213> artificial

<220>  
<223> conjugate of leader peptide, DS and DL domains of NKp44 with Fc domain

<400> 16

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu  
1 5 10 15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Gln  
20 25 30

Ser Lys Ala Gln Val Leu Gln Ser Val Ala Gly Gln Thr Leu Thr Val  
35 40 45

Arg Cys Gln Tyr Pro Pro Thr Gly Ser Leu Tyr Glu Lys Lys Gly Trp  
50 55 60

Cys Lys Glu Ala Ser Ala Leu Val Cys Ile Arg Leu Val Thr Ser Ser  
65 70 75 80

Lys Pro Arg Thr Val Ala Trp Thr Ser Arg Phe Thr Ile Trp Asp Asp  
85 90 95

Pro Asp Ala Gly Phe Phe Thr Val Thr Met Thr Asp Leu Arg Glu Glu  
Page 16

100	105	110
Asp Ser Gly His Tyr Trp Cys Arg Ile Tyr Arg Pro Ser Asp Asn Ser		
115	120	125
Val Ser Lys Ser Val Arg Phe Tyr Leu Val Val Ser Pro Ala Ser Ala		
130	135	140
Ser Thr Gln Thr Ser Trp Thr Pro Arg Asp Leu Val Ser Ser Gln Thr		
145	150	155
Gln Thr Gln Ser Cys Val Pro Pro Thr Ala Gly Ala Arg Gln Ala Pro		
165	170	175
Glu Ser Pro Ser Thr Ile Pro Val Pro Ser Gln Pro Gln Asn Ser Thr		
180	185	190
Leu Arg Pro Gly Pro Ala Ala Pro Asp Pro Glu Pro Lys Ser Ser Asp		
195	200	205
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Ala		
210	215	220
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile		
225	230	235
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu		
245	250	255
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His		
260	265	270
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg		
275	280	285
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys		
290	295	300
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu		
305	310	315
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr		
325	330	335
Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu		
340	345	350
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp		
355	360	365
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val		

370

375

380

Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp  
 385 390 395 400

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His  
 405 410 415

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro  
 420 425 430

Gly Lys

&lt;210&gt; 17

&lt;211&gt; 326

&lt;212&gt; PRT

&lt;213&gt; artificial

&lt;220&gt;

&lt;223&gt; conjugate of CD5 leader peptide and DS domain of NKP44 with Fc domain

&lt;400&gt; 17

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu  
 1 5 10 15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Ser  
 20 25 30

Pro Ala Ser Ala Ser Thr Gln Thr Ser Trp Thr Pro Arg Asp Leu Val  
 35 40 45

Ser Ser Gln Thr Gln Thr Gln Ser Cys Val Pro Pro Thr Ala Gly Ala  
 50 55 60

Arg Gln Ala Pro Glu Ser Pro Ser Thr Ile Pro Val Pro Ser Gln Pro  
 65 70 75 80

Gln Asn Ser Thr Leu Arg Pro Gly Pro Ala Ala Pro Asp Pro Glu Pro  
 85 90 95

Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu  
 100 105 110

Phe Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp  
 115 120 125

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp  
 130 135 140

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly  
 145 150 155 160

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn  
 165 170 175  
 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp  
 180 185 190  
 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro  
 195 200 205  
 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu  
 210 215 220  
 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn  
 225 230 235 240  
 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile  
 245 250 255  
 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr  
 260 265 270  
 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys  
 275 280 285  
 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys  
 290 295 300  
 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu  
 305 310 315 320  
 Ser Leu Ser Pro Gly Lys  
 325

&lt;210&gt; 18

&lt;211&gt; 376

&lt;212&gt; PRT

&lt;213&gt; artificial

&lt;220&gt;

&lt;223&gt; conjugate of leader peptide, and DL domain of Nkp44 with Fc domain

&lt;400&gt; 18

Met Gly Met Pro Met Gly Ser Phe Gln Pro Leu Ala Thr Leu Tyr Leu  
 1 5 10 15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Gln  
 20 25 30

Ser Lys Ala Gln Val Leu Gln Ser Val Ala Gly Gln Thr Leu Thr Val  
 35 40 45



Arg Cys Gln Tyr Pro Pro Thr Gly Ser Leu Tyr Glu Lys Lys Gly Trp  
 50 55 60  
 Cys Lys Glu Ala Ser Ala Leu Val Cys Ile Arg Leu Val Thr Ser Ser  
 65 70 75 80  
 Lys Pro Arg Thr Val Ala Trp Thr Ser Arg Phe Thr Ile Trp Asp Asp  
 85 90 95  
 Pro Asp Ala Gly Phe Phe Thr Val Thr Met Thr Asp Leu Arg Glu Glu  
 100 105 110  
 Asp Ser Gly His Tyr Trp Cys Arg Ile Tyr Arg Pro Ser Asp Asn Ser  
 115 120 125  
 Val Ser Lys Ser Val Arg Phe Tyr Leu Val Val Ser Pro Ala Asp Pro  
 130 135 140  
 Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala  
 145 150 155 160  
 Pro Glu Phe Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro  
 165 170 175  
 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val  
 180 185 190  
 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val  
 195 200 205  
 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln  
 210 215 220  
 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln  
 225 230 235 240  
 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala  
 245 250 255  
 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro  
 260 265 270  
 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr  
 275 280 285  
 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser  
 290 295 300  
 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr  
 305 310 315 320

Page 21

<400> 20  
 tccccactgc tcagcactta ggccggcaga atctgagcga tgtcttccac actccctgcc 60  
 ctgctctgcg tcgggctgtg tctgagtcag aggatcagcg cccagcagca gactctccca 120  
 aaaccgttca tctgggccga gcccatttc atggttccaa aggaaaagca agtgaccatc 180  
 tggtgccagg gaaattatgg ggctgttgaa taccagctgc actttgaagg aagccttttt 240  
 gccgtggaca gaccaaacc ccctgagcgg attaacaag tcaaattcta catcccggac 300  
 atgaactccc gcatggcagg gcaatacagc tgcattctatc gggttgggga gctctggtca 360  
 gagcccagca acttgctgga tctggtgga acagaaatgt atgacacacc caccctctcg 420  
 gttcatcctg gacccgaagt gatctcggga gagaaggat ccttctactg ccgtctagac 480  
 actgcaaca gcatgttctt actgctcaag gaggaagat ccagccacgt acagcgcgga 540  
 tacgggaagg tccaggcgga gttccccctg ggccctgtga ccacagccca ccgagggaca 600  
 taccgatgtt ttggctccta taacaaccat gcctggctt tccccagtga gccagtgaag 660  
 ctctggtca caggcgacat tgagaacacc agccttgac ctgaagacc cacccttctt 720  
 gcagacactt ggggcaccta cttttaacc acagagacgg gactccagaa agaccatgcc 780  
 ctctgggatc aactgcccc ggatccggag cccaaatctt ctgacaaaac tcacacatgc 840  
 ccaccgtgcc cagcacctga attcgagggt gcaccgtcag tcttctctt cccccaaaa 900  
 cccaaggaca cctcatgat ctcccgacc cctgaggat catgcgtggt ggtggacgtg 960  
 agccacgaag accctgaggt caagttcaac tggtagctgg acggcgtgga ggtgcataat 1020  
 gccaaagaca agccgcggga ggagcagtag aacagcacgt accgtgtggt cagcgtcctc 1080  
 accgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaagg ctccaacaaa 1140  
 gccctcccag ccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagagcca 1200  
 cagggtgtaca ccctgcccc atcccgggat gagctgacca agaaccagg cagcctgacc 1260  
 tgctggtca aaggcttcta tcccagcgac atcgccgtgg agtgggagag caatgggcag 1320  
 ccggagaaca actacaagac cagcctccc gtgctggact ccgacggctc cttcttctc 1380  
 tacagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt ctcattgtcc 1440  
 gtgatgcatg aggctctgca caaccactac acgcagaaga gcctctccct gtctccgggt 1500  
 aaatga 1506

<210> 21  
 <211> 1110  
 <212> DNA  
 <213> artificial

<220>  
 <223> DNA encoding conjugate of CD5 leader peptide and D1 domain of NKP46 with Fc domain (SEQ ID NO:10)

<400> 21  
 aagcttgccg ccaccatggg aatgccccatg gggctctctgc aaccgctggc caccttgtag 60  
 ctgctgggga tgctggctgc ttctgcctc ggacgggtca gggtagccca gcagcagact 120

```

ctcccaaac cgttcatctg ggccgagccc catttcatgg ttccaaagga aaagcaagtg 180
accatctggt gccagggaaa ttatggggct gttgaatacc agctgcactt tgaaggaagc 240
ctttttgccg tggacagacc aaaacccctt gagcggatta acaaagtcaa attctacatc 300
ccggacatga actcccgcat ggcagggcaa tacagctgca tctatcgggt tggggagctc 360
tggtcagagc ccagcaactt gctggatctg gtggaacag aaatggatcc ggagcccaaa 420
tcttctgaca aaactcacac atgcccaccg tgcccagcac ctgaattcga ggggtgcaccg 480
tcagtcttcc tcttcccccc aaaaccaag gacaccctca tgatctcccg gaccctgag 540
gtcacatgcg tgggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac 600
gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacaacagc 660
acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag 720
tacaagtgca aggtctccaa caaagccctc ccagcccca tcgagaaaac catctccaaa 780
gccaaagggc agccccgaga gccacaggtg tacaccctgc ccccatcccg ggatgagctg 840
accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc 900
gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc tcccgtgctg 960
gactccgacg gtccttctt cctctacagc aagctcaccg tggacaagag caggtggcag 1020
caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag 1080
aagagcctct ccctgtctcc gggtaaatga 1110

```

<210> 22  
 <211> 1197  
 <212> DNA  
 <213> artificial

<220>  
 <223> DNA encoding conjugate of leader peptide and D2 domain of NKP46  
 with Fc domain (SEQ ID NO:12)

```

<400> 22
aagcttgccg ccacatggg aatgcccag gggtctctgc aaccgctggc caccttgtag 60
ctgctgggga tgctggctgc ttctgcctc ggacggctca gggtagccta tgacacaccc 120
accctctcgg ttcatcctgg acccgaggtg atctcgggag agaaggtagc cttctactgc 180
cgtctagaca ctgcaacaag catgttctta ctgctcaagg agggaagatc cagccacgta 240
cagcgcggat acgggaaggc ccaggcggag ttccccctgg gccctgtgac cacagcccac 300
cgagggacat accgatgttt tggctcctat aacaaccatg cctgggtcttt cccagtgag 360
ccagtgaagc tcctggtcac aggcgacatt gagaacacca gccttgacc tgaagacccc 420
accttctctg acacttgggg cacctacctt ttaaccacag agacgggact ccagaaagac 480
catgccctct gggatccgga gcccaaatct tctgacaaaa ctacacatg cccaccgtgc 540
ccagcacctg aattcgaggg tgcaccgtca gtcttctct tcccccaaa acccaaggac 600
acctcatga tctcccgac ccctgaggtc acatgcgtgg tggtaggacgt gagccacgaa 660

```

gaccctgagg tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca 720  
 aagccgcggg aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg 780  
 caccaggact ggctgaatgg caaggagtac aagtgcagg tctccaacaa agccctccca 840  
 gccccatcg agaaaacat ctcaaagcc aaagggcagc cccgagagcc acaggtgtac 900  
 accctgcccc catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc 960  
 aaaggcttct atcccagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac 1020  
 aactacaaga ccacgcctcc cgtgctggac tccgacggct ctttcttcct ctacagcaag 1080  
 ctcaccgtgg acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat 1140  
 gaggctctgc acaaccacta cacgcagaag agcctctccc tgtctccggg taaatga 1197

<210> 23  
 <211> 606  
 <212> DNA  
 <213> homo sapiens

<300>  
 <308> NCBI/BC052582  
 <309> 2004-06-30  
 <313> (1)..(606)

<400> 23  
 atggcctgga tgctgttgct catcttgatc atggtccatc caggatcctg tgctctctgg 60  
 gtgtcccagc cccctgagat tcgtaccctg gaaggatcct ctgccttcct gccctgctcc 120  
 ttcaatgcc a gccaagggag actggccatt ggctccgtca cgtgggtccg agatgagggtg 180  
 gttccaggg a aggaggtgag gaatggaacc ccagagttca ggggccgcct ggccccactt 240  
 gcttcttccc gtttcttcca tgaccaccag gctgagctgc acatccggga cgtgcgaggc 300  
 catgacgcca gcatctacgt gtgcagagtg gaggtgctgg gccttggtgt cgggacaggg 360  
 aatgggactc ggctgggtgt ggagaaagaa catcctcagc taggggctgg tacagtcctc 420  
 ctcttccggg ctggattcta tgctgtcagc tttctctctg tggccgtggg cagcaccgtc 480  
 tattaccagg gcaaatgtct gacctggaaa ggtccaagaa ggcagctgcc ggctgtggtc 540  
 ccagcgcgcc tcccaccacc atgtgggagc tcagcacatc tgcttcccc agtcccagga 600  
 ggctga 606

<210> 24  
 <211> 1164  
 <212> DNA  
 <213> artificial

<220>  
 <223> DNA encoding conjugate of CD5 leader peptide, D1 and D2 domains  
 of NKp30 with Fc domain (SEQ ID NO:13)

<400> 24  
 aagcttgccg ccaccatggg aatgcccatt gggctctctg aaccgctggc caccttgtag 60  
 ctgctgggga tgctggctgc ttctgcctc ggacggctca gggtagccct ctgggtgtcc 120  
 cagccccttg agattcgtac cctggaaggg tcttctgcct tcctgccctg ctcttcaat 180

```

gccagccaag ggagactggc cattggctcc gtcacgtggt tccgagatga ggtggttcca 240
gggaaggagg tgaggaatgg aacccagag ttcaggggcc gcctggcccc acttgcttct 300
tcccgtttcc tccatgacca ccaggctgag ctgcacatcc gggacgtgcg aggccatgac 360
gccagcatct acgtgtgcag agtggagggtg ctgggccttg gtgtcgggac agggaatggg 420
actcggctgg tgggtggagaa agaacatcct cagctagggg atccggagcc caaatcttct 480
gacaaaactc acacatgccc accgtgcccc gcacctgaat tcgaggggtgc accgtcagtc 540
ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca 600
tgctgtggtg tggacgtgag ccacgaagac cctgagggtca agttcaactg gtacgtggac 660
ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac 720
cgtgtgtgca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag 780
tgcaagggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa 840
gggcagcccc gagagccaca ggtgtacacc ctgcccccat cccgggatga gctgaccaag 900
aaccagggtca gcctgacctg cctgggtcaaa ggcttctatc ccagcgacat cgccgtggag 960
tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc 1020
gacggctcct tcttcctcta cagcaagctc accgtggaca agagcagggtg gcagcagggg 1080
aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc 1140
ctctccctgt ctccgggtaa atga 1164

```

```

<210> 25
<211> 854
<212> DNA
<213> homo sapiens

```

```

<300>
<308> NCBI/AJ225109
<309> 1999-03-15
<313> (1)..(854)

```

```

<400> 25
atggcctggc gagccctaca cccactgcta ctgctgtgctg tgctgttccc aggctctcag 60
gcacaatcca aggctcaggt acttcaaagt gtggcagggc agacgctaac cgtgagatgc 120
cagtaccgcg ccacgggcag tctctacgag aagaaaggct ggtgtaagga ggcttcagca 180
cttgtgtgca tcaggttagt caccagctcc aagcccagga cgatggcttg gacctctcga 240
ttcacaatct gggacgacct tgatgctggc ttcttctactg tcaccatgac tgatctgaga 300
gaggaagact caggacatta ctggtgtaga atctaccgcc cttctgacaa ctctgtctct 360
aagtccgtca gattctatct ggtggtatct ccagcctctg cctccacaca gacccctgg 420
actccccgcg acctggtctc ttcacagacc cagaccaga gctgtgtgcc tcccactgca 480
ggagccagac aagcccctga gtctccatct accatccctg tcccttcaca gccacagaac 540
tccacgtccc gccctggccc tgcagcccc attgccctgg tgccctgtgtt ctgtggactc 600
ctcgtagcca agagcctggg gctgtcagcc ctgctcgtct ggtgggggga catatggtgg 660

```

```

aaaaccgtga tggagctcag gagcctggat acccaaaaag ccacctgcca ccttcaacag    720
gtcacggacc ttccctggac ctacagtttcc tcacctgtag agagagaaat attatatcac    780
actgtttcaa ggactaagat aagcgatgat gatgatgaac acactttgtg aataataaaa    840
ttatctgaat gttt                                                    854

```

<210> 26  
 <211> 1320  
 <212> DNA  
 <213> artificial

<220>  
 <223> DNA encoding conjugate of leader peptide, DS and DL domains of NKp44 with Fc domain (SEQ ID NO:15)

```

<400> 26
aagcttgccg ccaccatggg aatgcccattg gggctctctgc aaccgctggc caccttgtac    60
ctgctgggga tgctggctcg ttccctgcctc ggacggctca gggtagccca atccaaggct    120
caggtacttc aaagtgtggc agggcagacg ctaaccgtga gatgccagta cccgcccacg    180
ggcagtctct acgagaagaa aggctgggtg aaggaggctt cagcacttgt gtgcatcagg    240
ttagtcacca gtcceaagcc caggacggtg gcttggacct ctcgattcac aatctgggac    300
gaccttgatg ctggcttctt cactgtcacc atgactgatc tgagagagga agactcagga    360
cattactggt gtagaatcta ccgcccttct gacaactctg tctctaagtc cgtcagattc    420
tatctggtgg tatctccagc ctctgcctcc acacagacct cctggactcc ccgcgacctg    480
gtctcttcac agaccagac ccagagctgt gtgcctccca ctgcaggagc cagacaagcc    540
cctgagtctc catctacat ccctgtccct tcacagccac agaactccac gctccgcctt    600
ggccctgcag ccccgatcc ggagcccaaa tcttctgaca aaactcacac atgccaccg    660
tgcccagcac ctgaattcga ggggtgcaccg tcagtcttcc tcttcccccc aaaaccacaag    720
gacaccctca tgatctcccg gacccttgag gtcacatgct tgggtggtgga cgtgagccac    780
gaagaccctg aggtcaagtt caactggtac gtggacggcg tggagggtgca taatgccaag    840
acaaagccgc gggaggagca gtacaacagc acgtaccgtg tggtcagcgt cctcacgctc    900
ctgcaccagg actggctgaa tggcaaggag tacaagtgca aggtctccaa caaagccctc    960
ccagccccca tcgagaaaac catctccaaa gccaaagggc agccccgaga gccacagggtg    1020
tacaccctgc ccccatcccg ggatgagctg accaagaacc aggtcagcct gacctgcctg    1080
gtcaaaggct tctatcccag cgacatcgcc gtggagtggg agagcaatgg gcagccggag    1140
aacaactaca agaccacgcc tcccgtgctg gactccgacg gtccttctt cctctacagc    1200
aagctcaccg tggacaagag cagggtggcag caggggaacg tcttctcatg ctccgtgatg    1260
catgaggctc tgcacaacca ctacacgcag aagagcctct ccctgtctcc gggtaaatga    1320

```

<210> 27  
 <211> 996  
 <212> DNA

<213> artificial

<220>

<223> DNA encoding conjugate of CD5 leader peptide and DS domain of NKp44 with Fc domain (SEQ ID NO:16)

<400> 27

```

aagcttgccg ccacatggg aatgcccacg gggctctctg aaccgctggc caccttgtag      60
ctgctgggga tgctggctgc ttctgcctc ggacggctca gggtagcctc tccagcctct      120
gcctccacac agacctcctg gactccccgc gacctggtct cttcacagac ccagaccag      180
agctgtgtgc ctccactgc aggagccaga caagcccctg agtctccatc taccatccct      240
gtcccttcac agccacagaa ctccacgctc cgccctggcc ctgcagcccc ggatccggag      300
cccaaattct ctgacaaaac tcacacatgc ccaccgtgcc cagcacctga attcgagggg      360
gcaccgtcag tcttctctt cccccaaaa cccaaggaca cctcatgat ctcccgacc      420
cctgaggtca catgctgtgt ggtggacgtg agccacgaag accctgaggt caagttcaac      480
tggtacgtgg acggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagtag      540
aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc      600
aaggagtaca agtgcaaggt ctccaacaaa gccctcccag ccccatcga gaaaaccatc      660
tccaaagcca aagggcagcc ccgagagcca caggtgtaca ccctgcccc atccgggat      720
gagctgacca agaaccaggt cagcctgacc tgcctggtca aaggcttcta tcccagcgac      780
atcgccgtgg agtgggagag caatgggcag ccggagaaca actacaagac cagcctccc      840
gtgctggact ccgacggtc cttcttcctc tacagcaagc tcaccgtgga caagagcagg      900
tggcagcagg ggaacgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac      960
acgcagaaga gcctctccct gtctccgggt aaatga                                996

```

<210> 28

<211> 1146

<212> DNA

<213> artificial

<220>

<223> DNA encoding conjugate of CD5 leader peptide and DL domain of NKp44 with Fc domain (SEQ ID NO:17)

<400> 28

```

aagcttgccg ccacatggg aatgcccacg gggctctctg aaccgctggc caccttgtag      60
ctgctgggga tgctggctgc ttctgcctc ggacggctca gggtagccca atccaaggct      120
caggtacttc aaagtgtggc agggcagacg ctaaccgtga gatgccagta cccgcccacg      180
ggcagtctct acgagaagaa aggctggtgt aaggaggctt cagcacttgt gtgcatcagg      240
ttagtcacca gctccaagcc caggacggtg gcttgacct ctcgattcac aatctgggac      300
gacctgatg ctggcttctt cactgtcacc atgactgac tgagagagga agactcagga      360
cattactggt gtagaatcta ccgcccttct gacaactctg tctctaagtc cgtcagattc      420
tatctggtgg tatctccagc ggatccggag cccaaattct ctgacaaaac tcacacatgc      480

```



ccaccgtgcc cagcacctga attcgaggggt gcaccgtcag tcttcctctt ccccccaaaa 540  
 cccaaggaca ccctcatgat ctcccgacc cctgaggtca catgcgtggt ggtggacgtg 600  
 agccacgaag accctgaggt caagttcaac tggtagctgg acggcgtgga ggtgcataat 660  
 gccaaagaaa agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtcctc 720  
 accgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa 780  
 gccctcccag ccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagagcca 840  
 caggtgtaca ccctgcccc atcccgggat gagctgacca agaaccaggt cagcctgacc 900  
 tgcctggtca aaggcttcta tcccagcgac atcgccgtgg agtgggagag caatgggcag 960  
 ccggagaaca actacaagac cagcctccc gtgctggact ccgacggctc cttcttcctc 1020  
 tacagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt ctcatgctcc 1080  
 gtgatgcatg aggctctgca caaccactac acgcagaaga gcctctccct gtctccgggt 1140  
 aatga 1146

<210> 29  
 <211> 159  
 <212> PRT  
 <213> Artificial

<220>  
 <223> conjugate of CD5 leader and mutated Nkp46 (Q4) with Fc of Ig  
 <400> 29

Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu  
 1 5 10 15

Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Tyr  
 20 25 30

Asp Thr Pro Thr Leu Ser Val His Pro Gly Pro Glu Val Ile Ser Gly  
 35 40 45

Glu Lys Val Thr Phe Tyr Cys Arg Leu Asp Thr Ala Thr Ser Met Phe  
 50 55 60

Leu Leu Leu Gln Glu Gly Gln Ser Ser Gln Val Gln Gln Gly Tyr Gly  
 65 70 75 80

Lys Val Gln Ala Glu Phe Pro Leu Gly Pro Val Thr Thr Ala His Arg  
 85 90 95

Gly Thr Tyr Arg Cys Phe Gly Ser Tyr Asn Asn His Ala Trp Ser Phe  
 100 105 110

Pro Ser Glu Pro Val Lys Leu Leu Val Thr Gly Asp Ile Glu Asn Thr  
 115 120 125

Ser Leu Ala Pro Glu Asp Pro Thr Phe Pro Asp Thr Trp Gly Thr Tyr  
 Page 28

130                                      135                                      140  
 Leu Leu Thr Thr Glu Thr Gly Leu Gln Lys Asp His Ala Leu Trp  
 145                                      150                                      155  
  
 <210> 30  
 <211> 159  
 <212> PRT  
 <213> Artificial  
  
 <220>  
 <223> conjugate of CD5 leader and mutated Nkp46 (Q4T1) with Fc of Ig  
  
 <400> 30  
 Met Gly Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu  
 1                                      5                                      10                                      15  
  
 Leu Gly Met Leu Val Ala Ser Cys Leu Gly Arg Leu Arg Val Pro Tyr  
                                     20                                      25                                      30  
  
 Asp Thr Pro Thr Leu Ser Val His Pro Gly Pro Glu Val Ile Ser Gly  
                                     35                                      40                                      45  
  
 Glu Lys Val Thr Phe Tyr Cys Arg Leu Asp Thr Ala Thr Ser Met Phe  
                                     50                                      55                                      60  
  
 Leu Leu Leu Gln Glu Gly Gln Ser Ser Gln Val Gln Gln Gly Tyr Gly  
 65                                      70                                      75                                      80  
  
 Thr Val Gln Ala Glu Phe Pro Leu Gly Pro Val Thr Thr Ala His Arg  
                                     85                                      90                                      95  
  
 Gly Thr Tyr Arg Cys Phe Gly Ser Tyr Asn Asn His Ala Trp Ser Phe  
                                     100                                      105                                      110  
  
 Pro Ser Glu Pro Val Lys Leu Leu Val Thr Gly Asp Ile Glu Asn Thr  
                                     115                                      120                                      125  
  
 Ser Leu Ala Pro Glu Asp Pro Thr Phe Pro Asp Thr Trp Gly Thr Tyr  
                                     130                                      135                                      140  
  
 Leu Leu Thr Thr Glu Thr Gly Leu Gln Lys Asp His Ala Leu Trp  
 145                                      150                                      155

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
9 June 2005 (09.06.2005)

PCT

(10) International Publication Number  
**WO 2005/051973 A3**

(51) International Patent Classification:

A61K 38/00 (2006.01) C12P 21/08 (2006.01)  
A61K 39/395 (2006.01) G01N 33/574 (2006.01)

(21) International Application Number:

PCT/IL2004/001081

(22) International Filing Date:

24 November 2004 (24.11.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/524,648 25 November 2003 (25.11.2003) US

(71) Applicants (for all designated States except US): YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; High Tech Park, Edmond J. Safra Campus, P.O. Box 39135, 91390 Givat Ram, Jerusalem (IL). BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY [IL/IL]; P.O. Box 653, 84105 Beer-Sheva (IL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MANDELBOIM, Ofer [IL/IL]; 58 Hayarden Street, 73142 Shoham (IL). PORGADOR, Angel [IL/IL]; 11 Tavlan Street, 85338 Lehavim (IL).

(74) Agent: WEBB, Cynthia; Webb & Associates, P.O. Box 2189, 76121 Rehovot (IL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

24 August 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PEPTIDES DERIVED FROM NATURAL CYTOTOXICITY RECEPTORS AND METHODS OF USE THEREOF

(57) Abstract: The present invention relates in general to specific NCR-derived peptides capable of binding to membrane-associated biomolecules of the tumor cells, said biomolecules comprising at least one sulfated polysaccharide. Preferred peptides are about 7 to about 120 amino acids in length and are derived from NKp-44, NKp30 or NKp46.

WO 2005/051973 A3

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL04/01081

## A. CLASSIFICATION OF SUBJECT MATTER

IPC: A61K 38/00( 2006.01);39/395( 2006.01);C12P 21/08( 2006.01);G01N 33/574( 2006.01)

USPC: 424/141.1;435/7.23;514/2;530/324,328,329,388.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/141.1;435/7.23;514/2;530/324,328,329,388.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
STIC searched SEQ ID NO: 1-5 against protein databases.

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/08287 A2 (YISUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM ) 31 January 2002 (31.01.2002), see entire document.	1-38 and 40

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	"T"
"A" document defining the general state of the art which is not considered to be of particular relevance	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 June 2006 (23.06.2006)

Date of mailing of the international search report

13 JUL 2006

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (571) 273-3201

Authorized officer

Marienne D'Erino, Ph.D.

Telephone No. 571-272-1600

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL04/01081

Continuation of B. FIELDS SEARCHED Item 3:

STN(EMBASE, BIOSIS, MEDLINE, CAPLUS, SCISEARCH, USPATFUL)

search terms: inventors' names, NKp44, NKp30, NKp46, tumor, sulfated polysaccharide, glycosaminoglycan, gag, proteoglycan, glypican, syndecan, heparin, dermatan, fragment, soluble)